{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain import document_loaders as dl\n",
    "from langchain import embeddings\n",
    "from langchain.chains.combine_documents import create_stuff_documents_chain\n",
    "from langchain import text_splitter as ts\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_community.docstore.in_memory import InMemoryDocstore\n",
    "from langchain_ollama import OllamaEmbeddings, ChatOllama\n",
    "from langchain_core.tools import tool\n",
    "import torch\n",
    "import faiss\n",
    "from typing import Annotated, Sequence, Literal, List\n",
    "from typing_extensions import TypedDict\n",
    "from langchain_core.messages import BaseMessage, HumanMessage\n",
    "from langgraph.graph.message import add_messages\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.prompts import PromptTemplate\n",
    "from pydantic import BaseModel, Field\n",
    "from langgraph.prebuilt import tools_condition\n",
    "from langgraph.prebuilt import create_react_agent\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "from langchain_core.messages import SystemMessage\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from IPython.display import Image, display\n",
    "import os\n",
    "from langchain import hub\n",
    "from langgraph.graph import END, StateGraph, START\n",
    "from langgraph.prebuilt import ToolNode\n",
    "import json\n",
    "os.environ[\"KMP_DUPLICATE_LIB_OK\"]=\"TRUE\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc_path = 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf'\n",
    "loader = dl.PyPDFLoader(doc_path)\n",
    "\n",
    "doc = loader.load()\n",
    "text_splitter = ts.RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=200)\n",
    "\n",
    "all_splits = text_splitter.split_documents(doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/35 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 35/35 [00:29<00:00,  1.19it/s]\n"
     ]
    }
   ],
   "source": [
    "dir_path = 'C:/Users/Carlini/OneDrive - Alma Mater Studiorum Università di Bologna/Articoli/MS'\n",
    "\n",
    "loader = dl.DirectoryLoader(dir_path, glob='*.pdf', loader_cls=dl.PyPDFLoader, show_progress=True)\n",
    "doc = loader.load()\n",
    "\n",
    "text_splitter = ts.RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=200)\n",
    "\n",
    "all_splits = text_splitter.split_documents(doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = OllamaEmbeddings(model=\"mxbai-embed-large\")\n",
    "\n",
    "index = faiss.IndexFlatL2(len(embeddings.embed_query(\"Hello world!\")))\n",
    "\n",
    "vector_store = FAISS(embedding_function=embeddings, index=index, docstore=InMemoryDocstore(), index_to_docstore_id={})\n",
    "\n",
    "_ = vector_store.add_documents(all_splits)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vector_store.as_retriever(search_kwargs={\"k\": 5})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "memory = MemorySaver()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "class AgentState(TypedDict):\n",
    "    messages: Annotated[Sequence[BaseMessage], add_messages]\n",
    "    user_question: str\n",
    "    documents: List[str]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve(state):\n",
    "    \"\"\"\n",
    "    Retrieve documents from a vector store based on a query.\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (AgentState): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    dict: The updated state with the retrieved documents appended to messages\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---RETRIEVE INVOKED---\")\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "\n",
    "    question = messages[-1].content\n",
    "\n",
    "    documents = retriever.invoke(question)\n",
    "\n",
    "    return {\"documents\": documents}\n",
    "\n",
    "def summarize(state):\n",
    "    \"\"\"\n",
    "    Summarize the retrieved documents.\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (AgentState): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    dict: The updated state with the summarized documents appended to messages\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---SUMMARIZE INVOKED---\")\n",
    "\n",
    "    prompt = ChatPromptTemplate.from_messages(\n",
    "    [(\"human\", \"Write a summary of the following:\\\\n\\\\n{context}\")]\n",
    ")\n",
    "\n",
    "    model = ChatOllama(model=\"llama3.2:3b-instruct-fp16\", temperature=0)\n",
    "\n",
    "    chain = create_stuff_documents_chain(model, prompt)\n",
    "\n",
    "    result = chain.invoke({\"context\": doc})\n",
    "\n",
    "    return {\"messages\": [result]}\n",
    "\n",
    "def grade_documents(state) -> Literal[\"generate_rag\", \"rewrite\"]:\n",
    "    \"\"\"\n",
    "    Determines whether the retrieved documents are relevant to the user query.\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (messages): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    decision: A string indicating the decision\n",
    "    \"\"\"\n",
    "\n",
    "\n",
    "    model = ChatOllama(model=\"llama3.2:3b-instruct-fp16\", temperature=0, format=\"json\")\n",
    "\n",
    "    prompt = PromptTemplate(\n",
    "        template=\"\"\"You are a grader assessing relevance of a retrieved document to a user question. \\n \n",
    "        Here is the retrieved document: \\n\\n {context} \\n\\n\n",
    "        Here is the user question: {question} \\n\n",
    "        If the document contains keyword(s) or semantic meaning related to the user question, grade it as relevant. \\n\n",
    "        Give a binary score 'yes' or 'no' score to indicate whether the document is relevant to the question.\n",
    "        Return a JSON with single key 'binary_score', that is either 'yes' of 'no', depending on your decision.\"\"\",\n",
    "        input_variables=[\"context\", \"question\"],\n",
    "    )\n",
    "\n",
    "    chain = prompt | model\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "\n",
    "    question = messages[-1].content\n",
    "    docs = state[\"documents\"]\n",
    "\n",
    "    response = chain.invoke({\"context\": docs, \"question\": question})\n",
    "\n",
    "    score = json.loads(response.content)[\"binary_score\"]\n",
    "\n",
    "    if score == \"yes\":\n",
    "        print(\"---DECISION: DOCS RELEVANT---\")\n",
    "        return \"generate_rag\"\n",
    "    else:\n",
    "        print(\"---DECISION: DOCS NOT RELEVANT---\")\n",
    "        return \"rewrite\"\n",
    "\n",
    "\n",
    "def agent(state):\n",
    "    \"\"\"\n",
    "    Invokes the agent model to generate a response based on the current state.\n",
    "    Given the question, it will decide to retrieve using the retriever tool, or simply end.\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (messages): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    dict: The updated state with the agent response appended to messages\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---AGENT INVOKED---\")\n",
    "\n",
    "    template = \"\"\"\n",
    "    You are an AI assistant that can help answer questions.\n",
    "    Given the user question, decide what to do. Your options are to generate an answer, to retrieve documents\n",
    "    or to summarize the documents.\n",
    "    Here is the user question: {question}\n",
    "    Return a JSON with single key 'decision', that is either 'generate', 'retrieve' or 'summarize', depending on the question.\n",
    "    \"\"\"\n",
    "\n",
    "    prompt = PromptTemplate(\n",
    "        template=template,\n",
    "        input_variables=[\"question\"],\n",
    "    )\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "    user_question = messages[-1].content\n",
    "    model = ChatOllama(model=\"llama3-groq-tool-use:8b-fp16\", temperature=0, format=\"json\")\n",
    "    \n",
    "    chain = prompt | model\n",
    "\n",
    "    response = chain.invoke(user_question)\n",
    "\n",
    "    decision = json.loads(response.content)[\"decision\"]\n",
    "\n",
    "    if decision == \"generate\":\n",
    "        print(\"---DECISION: GENERATE---\")\n",
    "        return \"generate\"\n",
    "    elif decision == \"retrieve\":\n",
    "        print(\"---DECISION: RETRIEVE---\")\n",
    "        return \"retrieve\"\n",
    "    elif decision == \"summarize\":\n",
    "        print(\"---DECISION: SUMMARIZE---\")\n",
    "        return \"summarize\"\n",
    "\n",
    "\n",
    "def rewrite(state):\n",
    "    \"\"\"\n",
    "    Transform the query to produce a better question.\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (messages): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    dict: The updated state with the transformed question appended to messages\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---REWRITE INVOKED---\")\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "    question = messages[-1].content\n",
    "\n",
    "    msg = [\n",
    "        HumanMessage(\n",
    "            content=f\"\"\"\\n\n",
    "        Look at the input and try to reason about the undelying semantic intent / meaning. \\n\n",
    "        Here is the initial question: \n",
    "        \\n ----------------- \\n \n",
    "        {question} \n",
    "        \\n ----------------- \\n\n",
    "        Formulate an improved question. Generate the new question only,\n",
    "        not your reasoning.\n",
    "        New question: \"\"\",\n",
    "        )\n",
    "    ]\n",
    "\n",
    "    model = ChatOllama(model=\"llama3.2:3b-instruct-fp16\")\n",
    "    response = model.invoke(msg)\n",
    "\n",
    "    return {\"messages\": [response]}\n",
    "\n",
    "def generate(state):\n",
    "    \"\"\"\n",
    "    Generate an answer without retrieving documents.\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---GENERATE INVOKED---\")\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "    # question = state[\"user_question\"]\n",
    "\n",
    "    model = ChatOllama(model=\"llama3.2:3b-instruct-fp16\", temperature=0)\n",
    "\n",
    "    response = model.invoke(messages)\n",
    "\n",
    "    return {\"messages\": [response]}\n",
    "\n",
    "def generate_rag(state):\n",
    "    \"\"\"\n",
    "    Generate answer\n",
    "\n",
    "    Parameters\n",
    "    ----------\n",
    "    state (messages): The current state\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    dict: The updated state with the generated answer appended to messages\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"---GENERATE RAG INVOKED---\")\n",
    "\n",
    "    messages = state[\"messages\"]\n",
    "    documents = state[\"documents\"]\n",
    "\n",
    "    prompt = hub.pull(\"rlm/rag-prompt\")\n",
    "\n",
    "    llm = ChatOllama(model=\"llama3.2:3b-instruct-fp16\", temperature=0)\n",
    "\n",
    "    def format_docs(docs):\n",
    "        return \"\\n\\n\".join(doc.page_content for doc in docs)\n",
    "    \n",
    "    rag_chain = prompt | llm | StrOutputParser()\n",
    "\n",
    "    response = rag_chain.invoke({\"question\": messages[-1].content, \"context\": documents})\n",
    "\n",
    "    return {\"messages\": [response]}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "workflow = StateGraph(AgentState)\n",
    "\n",
    "workflow.add_node(\"retrieve\", retrieve)\n",
    "workflow.add_node(\"rewrite\", rewrite)\n",
    "workflow.add_node(\"generate_rag\", generate_rag)\n",
    "workflow.add_node(\"generate\", generate)\n",
    "workflow.add_node(\"summarize\", summarize)\n",
    "# workflow.add_edge(START, \"agent\")\n",
    "\n",
    "workflow.set_conditional_entry_point(\n",
    "    agent,\n",
    "    {\n",
    "        \"retrieve\": \"retrieve\",\n",
    "        \"generate\": \"generate\",\n",
    "        \"summarize\": \"summarize\",\n",
    "    }\n",
    ")\n",
    "\n",
    "workflow.add_conditional_edges(\n",
    "    \"retrieve\",\n",
    "    grade_documents,)\n",
    "\n",
    "workflow.add_edge(\"generate\", END)\n",
    "workflow.add_edge(\"generate_rag\", END)\n",
    "workflow.add_edge(\"summarize\", END)\n",
    "workflow.add_edge(\"rewrite\", \"retrieve\")\n",
    "\n",
    "graph = workflow.compile(checkpointer=memory)\n",
    "\n",
    "config = {\"configurable\": {\"thread_id\": \"abc123\"}}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---AGENT INVOKED---\n",
      "---DECISION: GENERATE---\n",
      "---GENERATE INVOKED---\n",
      "\"Output from node 'generate':\"\n",
      "'---'\n",
      "{ 'messages': [ AIMessage(content=\"Based on the documents you provided, here is a list of the most common disease-modifying drugs (DMDs) used to treat multiple sclerosis:\\n\\n1. **Interferons**: A class of proteins that help reduce inflammation and slow down disease progression.\\n2. **Glatiramer acetate**: An immunomodulator that helps reduce relapses and slow down disability progression.\\n3. **Fingolimod**: A sphingosine 1-phosphate receptor modulator that reduces lymphocyte circulation, leading to reduced inflammation and relapse rates.\\n4. **Dimethyl fumarate**: An immunomodulator that has anti-inflammatory properties and helps reduce relapses and disability progression.\\n5. **Teriflunomide**: An immunomodulator that inhibits the production of inflammatory cytokines and helps reduce relapses and disability progression.\\n6. **Alemtuzumab**: A monoclonal antibody that targets CD52, a protein on the surface of immune cells, reducing lymphocyte circulation and inflammation.\\n\\nThese DMDs are commonly used to slow down or reduce the number and severity of relapses, inflammation, and long-term disability in multiple sclerosis patients. However, it's essential to note that each patient's response to treatment may vary, and a healthcare professional should be consulted for personalized treatment recommendations.\\n\\nWould you like me to help with anything else?\", additional_kwargs={}, response_metadata={'model': 'llama3.2:3b-instruct-fp16', 'created_at': '2024-12-09T10:10:05.0215215Z', 'done': True, 'done_reason': 'stop', 'total_duration': 4239568600, 'load_duration': 14738600, 'prompt_eval_count': 1214, 'prompt_eval_duration': 149000000, 'eval_count': 279, 'eval_duration': 3769000000, 'message': Message(role='assistant', content='', images=None, tool_calls=None)}, id='run-654ee2e5-3153-4d01-9b7a-432a3eb76d54-0', usage_metadata={'input_tokens': 1214, 'output_tokens': 279, 'total_tokens': 1493})]}\n",
      "'\\n---\\n'\n"
     ]
    }
   ],
   "source": [
    "import pprint\n",
    "\n",
    "inputs = {\n",
    "    \"messages\": [\n",
    "        (\"user\", \"Tell me more\"),\n",
    "    ]\n",
    "}\n",
    "for output in graph.stream(inputs, config=config):\n",
    "    for key, value in output.items():\n",
    "        pprint.pprint(f\"Output from node '{key}':\")\n",
    "        pprint.pprint(\"---\")\n",
    "        pprint.pprint(value, indent=2, width=80, depth=None)\n",
    "    pprint.pprint(\"\\n---\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---AGENT INVOKED---\n",
      "---DECISION: RETRIEVE---\n",
      "---RETRIEVE INVOKED---\n",
      "---DECISION: DOCS RELEVANT---\n",
      "\"Output from node 'retrieve':\"\n",
      "'---'\n",
      "{ 'documents': [ Document(metadata={'source': 'C:\\\\Users\\\\Carlini\\\\OneDrive - Alma Mater Studiorum Università di Bologna\\\\Articoli\\\\MS\\\\a_deep_learning_approach_to_predicting_disease_ms.pdf', 'page': 7}, page_content='in the second row, an EDSS worsened patient wrongly classified as stable by the software.\\nStorelli et al Investigative Radiology \\x81 Volume 57, Number 7, July 2022\\n430 www.investigativeradiology.com © 2022 Wolters Kluwer Health, Inc. All rights reserved.\\nCopyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.\\nDownloaded from http://journals.lww.com/investigativeradiology by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 08/23/2024'),\n",
      "                 Document(metadata={'source': 'C:\\\\Users\\\\Carlini\\\\OneDrive - Alma Mater Studiorum Università di Bologna\\\\Articoli\\\\MS\\\\READ_a_deep_learning_approach_to_predicting_disease_ms.pdf', 'page': 7}, page_content='in the second row, an EDSS worsened patient wrongly classified as stable by the software.\\nStorelli et al Investigative Radiology \\x81 Volume 57, Number 7, July 2022\\n430 www.investigativeradiology.com © 2022 Wolters Kluwer Health, Inc. All rights reserved.\\nCopyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.\\nDownloaded from http://journals.lww.com/investigativeradiology by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 08/23/2024'),\n",
      "                 Document(metadata={'source': 'C:\\\\Users\\\\Carlini\\\\OneDrive - Alma Mater Studiorum Università di Bologna\\\\Articoli\\\\MS\\\\How patients with multiple sclerosis acquire disability.pdf', 'page': 2}, page_content='EDSS raters who were not otherwise involved in the treatment of\\nthe patients and had no access to treatment or clinical information\\n(EDSS-based disability criteria may be found inSupplementary\\nTable 2A). In the extension studies, EDSS was assessed at 3- or\\n6-monthly intervals by trained and certiﬁed EDSS raters who could\\nbe the treating physician. In the full dataset, EDSS collection could\\nbe more heterogeneous and depended on the study protocols.\\nAll trial protocols were approved by the appropriate institution-\\nal review boards or ethical committees and trials followed the prin-\\nciples of the Declaration of Helsinki and Good Clinical Practice. All\\npatients provided written informed consent. All clinical and MRI\\nscan data have been anonymized.18 The individual study results\\nhave been previously published elsewhere.\\nEnd point deﬁnitions\\nMultiple sclerosis relapses\\nMultiple sclerosis relapses were deﬁned as the appearance of a new'),\n",
      "                 Document(metadata={'source': 'C:\\\\Users\\\\Carlini\\\\OneDrive - Alma Mater Studiorum Università di Bologna\\\\Articoli\\\\MS\\\\s40120-021-00239-2.pdf', 'page': 16}, page_content='any medium or format, as long as you give\\nappropriate credit to the original author(s) and\\nthe source, provide a link to the Creative\\nCommons licence, and indicate if changes were\\nmade. The images or other third party material\\nin this article are included in the article’s\\nCreative Commons licence, unless indicated\\notherwise in a credit line to the material. If\\nmaterial is not included in the article’s Creative\\nCommons licence and your intended use is not\\npermitted by statutory regulation or exceeds the\\npermitted use, you will need to obtain permis-\\nsion directly from the copyright holder. To view\\na copy of this licence, visithttp://\\ncreativecommons.org/licenses/by-nc/4.0/.\\nREFERENCES\\n1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple\\nsclerosis. N Engl J Med. 2018;378(2):169–80.\\n2. White CP, White MB, Russell CS. Invisible and vis-\\nible symptoms of multiple sclerosis: which are more\\npredictive of health distress? J Neurosci Nurs.\\n2008;40(2):85–95 (102).'),\n",
      "                 Document(metadata={'source': 'C:\\\\Users\\\\Carlini\\\\OneDrive - Alma Mater Studiorum Università di Bologna\\\\Articoli\\\\MS\\\\Annals of Neurology - 2024 - Calabrese - Determinants and Biomarkers of Progression Independent of Relapses in Multiple.pdf', 'page': 12}, page_content='approach.\\nAuthor Contributions\\nM.C., P.P., A.S., E.C., D.M., M.A., M.B., N.D.S.,\\nM.D.F., S.H., O.W.H., M.I., H.L., R.M., R.N., R.R.,\\nM.A.R., A.T., M.V., L.M.V., M.F., and R.M. contrib-\\nuted to the conception and design of the study; M.C.,\\nP.P., A.S., E.C., D.M., M.A., M.B., N.D.S., M.D.F.,\\nS.H., O.W.H., M.I., H.L., R.M., R.N., R.R., M.A.R.,\\nA.T., M.V., L.M.V., M.F., and R.M. contributed to the\\nacquisition and analysis of data; M.C., P.P., A.S., E.C.,\\nD.M., M.A., M.B., N.D.S., M.D.F., S.H., O.W.H.,\\nM.I., H.L., R.M., R.N., R.R., M.A.R., A.T., M.V.,\\nL.M.V., M.F., and R.M. contributed to drafting the text\\nor preparing theﬁgures.\\nPotential Conﬂicts of Interest\\nM.C., P.P., A.S., E.C., D.M., M.A., M.B., N.D.S.,\\nM.D.F., S.H., O.W.H., M.I., H.L., R.M., R.N., R.R.,\\nM.A.R., A.T., M.V., L.M.V., M.F., and R.M. have noth-\\ning to report.\\nReferences\\n1. Lublin FD, Reingold SC, Cohen JA, et al. De ﬁning the clinical\\ncourse of multiple sclerosis: The 2013 revisions. Neurology 2014;\\n83:278–286.')]}\n",
      "'\\n---\\n'\n",
      "---GENERATE RAG INVOKED---\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Carlini\\miniconda3\\envs\\llama\\Lib\\site-packages\\langsmith\\client.py:241: LangSmithMissingAPIKeyWarning: API key must be provided when using hosted LangSmith API\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\"Output from node 'generate_rag':\"\n",
      "'---'\n",
      "{ 'messages': [ \"The word 'EDSS' is mentioned in three different documents. It \"\n",
      "                'refers to the Expanded Disability Status Scale, which is used '\n",
      "                'to assess disability in patients with multiple sclerosis. '\n",
      "                'EDSS raters are also mentioned as being involved in assessing '\n",
      "                'patients and collecting data on their disability status.']}\n",
      "'\\n---\\n'\n"
     ]
    },
    {
     "ename": "",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31mThe Kernel crashed while executing code in the current cell or a previous cell. \n",
      "\u001b[1;31mPlease review the code in the cell(s) to identify a possible cause of the failure. \n",
      "\u001b[1;31mClick <a href='https://aka.ms/vscodeJupyterKernelCrash'>here</a> for more info. \n",
      "\u001b[1;31mView Jupyter <a href='command:jupyter.viewOutput'>log</a> for further details."
     ]
    }
   ],
   "source": [
    "import pprint\n",
    "\n",
    "inputs = {\n",
    "    \"messages\": [\n",
    "        (\"user\", \"Is the word 'EDSS' mentioned in the document? Retrieve it from the documents\"),\n",
    "    ]\n",
    "}\n",
    "for output in graph.stream(inputs, config=config):\n",
    "    for key, value in output.items():\n",
    "        pprint.pprint(f\"Output from node '{key}':\")\n",
    "        pprint.pprint(\"---\")\n",
    "        pprint.pprint(value, indent=2, width=80, depth=None)\n",
    "    pprint.pprint(\"\\n---\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---AGENT INVOKED---\n",
      "---DECISION: GENERATE---\n",
      "---GENERATE INVOKED---\n",
      "\"Output from node 'generate':\"\n",
      "'---'\n",
      "{ 'messages': [ AIMessage(content=\"Hello! I'd be happy to help you understand the documents you have.\\n\\nThe main topic of these documents appears to be Multiple Sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. The articles cover various aspects of MS, including diagnosis, treatment, management, cognitive impairment, physical disability, comorbidity and social factors, and lifestyle and risk factors.\\n\\nAs for your question about Darth Plagueis the Wise... I'm not familiar with any legend or story about a character by that name. However, I do know that Darth Plagueis is a fictional character in the Star Wars universe. He's a Sith Lord who is said to have had the power to prevent people from dying, and his legend has become somewhat of a myth among fans.\\n\\nBut let's get back to your documents! If you'd like, I can help you summarize or analyze the articles further, or provide more information about MS if that would be helpful.\", additional_kwargs={}, response_metadata={'model': 'llama3.2:3b-instruct-fp16', 'created_at': '2024-12-09T10:01:10.5307332Z', 'done': True, 'done_reason': 'stop', 'total_duration': 2929301500, 'load_duration': 14613600, 'prompt_eval_count': 887, 'prompt_eval_duration': 84000000, 'eval_count': 192, 'eval_duration': 2521000000, 'message': Message(role='assistant', content='', images=None, tool_calls=None)}, id='run-9732f699-0079-40f1-8a91-8355f297321f-0', usage_metadata={'input_tokens': 887, 'output_tokens': 192, 'total_tokens': 1079})]}\n",
      "'\\n---\\n'\n"
     ]
    }
   ],
   "source": [
    "import pprint\n",
    "\n",
    "inputs = {\n",
    "    \"messages\": [\n",
    "        (\"user\", \"Have you ever heard of the legend of darth plagueis the wise?\"),\n",
    "    ]\n",
    "}\n",
    "for output in graph.stream(inputs, config=config):\n",
    "    for key, value in output.items():\n",
    "        pprint.pprint(f\"Output from node '{key}':\")\n",
    "        pprint.pprint(\"---\")\n",
    "        pprint.pprint(value, indent=2, width=80, depth=None)\n",
    "    pprint.pprint(\"\\n---\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 0}, page_content='1002 journals.sagepub.com/home/msj\\nMULTIPLE\\nSCLEROSIS MSJ\\nJOURNAL\\nhttps://doi.org/10.1177/13524585211001789\\nhttps://doi.org/10.1177/13524585211001789\\nMultiple Sclerosis Journal\\n2021, Vol. 27(7) 1002 –1007\\nDOI: 10.1177/ \\n13524585211001789\\n© The Author(s), 2021. \\n \\nArticle reuse guidelines:  \\nsagepub.com/journals-\\npermissions\\nMultiple Sclerosis Journal\\n2021, Vol. 27(7) 1002 –1004\\nDOI: 10.1177/ \\n13524585211001789\\n© The Author(s), 2021. \\n \\nArticle reuse guidelines:  \\nsagepub.com/journals-\\npermissions\\nOnly few multiple sclerosis (MS) patients escape the \\nprogressive course if they survive long enough. In the \\nmajority of cases, the progression supervenes after a \\nvariable latency from the onset of the relapsing remit-\\nting phase, but the clinical boundaries between the \\nrelapsing and the progressive course are often indis-\\ntinct. There are no surrogate markers or universally \\naccepted definition for the continuous unremitting \\ndisability accumulation and defining the clinical phe-\\nnotypes of MS can be challenging even for experi-\\nenced clinicians.\\nThe current phenotypical distinction of relapsing \\nremitting (RR), secondary progressive (SP) and pri-\\nmary progressive (PP) MS provides a standardized \\nterminology, which enhances homogeneity in clini-\\ncal trials. However, despite the variable patterns of \\nevolution, there are no biological reasons for discern-\\ning different phenotypes. Pathological mechanisms \\nunderlying acute attacks and progression are known \\nto be tightly intermingled and to occur concomitantly \\nsince the early phase of the disease, irrespective of \\nclinical symptoms. The same wide spectrum of cen-\\ntral nervous system tissue alterations is seen across \\nall stages, with only quantitative, rather than qualita-\\ntive differences.1 Both PP and SP MS share similar \\npathological features in respect of the extent of \\ninflammatory infiltrates, axonal damage and cortical \\ndemyelination.1 Epidemiological data corroborate a \\nunifying disease model of MS, with predominantly \\nage-related clinical phenotypes. By growing older, \\nthe risk of experiencing a progressive course propor-\\ntionally increases, while relapses gradually become \\nsparse and infrequent.2 Progressive MS patients, with \\nor without a preceding RR course, accumulate disa-\\nbility at very similar rate and share strikingly similar \\nmean age at onset of progression, indicating that \\nPPMS is preceded by an ‘asymptomatic RR phase’.3 \\nConsistent with this view, subjects with radiologi-\\ncally isolated syndrome can develop a PP course \\nyears after the incidental detection of white matter \\nabnormalities, confirming a protracted pre-progres-\\nsive prodrome with subclinical disease activity simi-\\nlar to RRMS.4\\nDespite being biologically active, progressive MS \\ncan remain clinically undetectable for years. Most \\nclinicians would be reluctant to document a progres-\\nsive accumulation of disability unrelated to clinical \\nattacks during the early stage of the RR phase. Based \\non the recently proposed objective definition of \\nSPMS, the attainment of at least expanded disability \\nstatus scale (EDSS) of 4 is required to mark the tran-\\nsition to the progressive phase.5 However, the clini-\\ncal progression can be uncovered in the early phase \\nof the disease, among patients with no permanent \\nmotor impairment, especially when relapses with \\npoor recovery, which can potentially cloud the pro-\\ngressive accumulation of disability, are uncommon. \\nThis was highlighted by George Ebers’ group by \\naddressing the clinical course of single attack pro-\\ngressive MS, which is a rare phenotype distinguished \\nby a single demyelinating  episode at onset, followed \\nsome years later by the progressive phase. Because \\nof the lack of ongoing relapses, in this subgroup, the \\nprogression mostly presented clinically with exer-\\ncise-induced ambulation worsening and could be \\npinpointed after 8 mean years from onset, at an aver-\\nage EDSS of 2, therefore much earlier than in classic \\nSPMS cases.6\\nIn line with these early intuitive observations, recent \\ndata indicate that a continuous progression independ-\\nent of relapsing activity (PIRA) is commonly observed \\nduring the RR phase. The pooled analysis of the two \\nOPERA trials demonstrated, in both the Interferon \\nand Ocrelizumab groups with a relatively short dis-\\nease duration (mean 6 years) and low baseline mean \\nEDSS score (= 2.8), an impressively large proportion \\nof patients (78% and 87%, respectively) accumulat-\\ning disability, which was unrelated to inflammatory \\nattacks and was mostly secondary to worsening of the \\nwalking impairment.7 This provides clinical evidence \\nof an early underlying progressive course despite the \\nMS can be considered a primary  \\nprogressive disease in all cases, but some patients have superimposed relapses – Yes\\nAntonio Scalfari\\nCorrespondence to: \\nA Scalfari  \\nCentre of Neuroscience, \\nDepartment of Medicine, \\nImperial College London, \\nCharing Cross Hospital, \\nFulham Palace Road, London \\nW6 8RF, UK. \\na.scalfari@imperial.ac.uk\\nAntonio Scalfari  \\nCentre of Neuroscience, \\nDepartment of Medicine, \\nImperial College London, \\nCharing Cross Hospital, \\nLondon, UK\\n1001789 MSJ0010.1177/13524585211001789Multiple Sclerosis JournalA Scalfari\\nresearch-article20212021\\nControversies in Multiple Sclerosis\\n'),\n",
       " Document(metadata={'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 1}, page_content='A Scalfari \\njournals.sagepub.com/home/msj 1003\\neffective therapeutic relapse suppression and should \\ncaution against using the lack of ongoing focal inflam-\\nmation as marker of disease stability. The adequate \\ncontrol of inflammatory parameters might provide a \\nsense of false security, while a continuous smoulder-\\ning process underpins the subtle clinical deterioration, \\nwhich stands out as an important unmet treatment tar-\\nget. Changes in the whole brain and grey matter vol-\\nume,7 the accumulation of chronic slowing expanding \\nlesions8 and the microglia activation, both in the nor -\\nmal appearing white matter and in the perilesional \\nareas,9 are plausible drivers of PIRA events during the \\nRR phase, when the focal inflammatory activity is the \\ndominant clinical feature, albeit representing only the \\ntip of the pathological iceberg.\\nThese observations challenge the dichotomy between \\nrelapsing and progressive disease, supporting a one \\nstage disorder model of MS, where all patients \\nexhibit a progressive course since the disease onset, \\nwhich can be overlapped by relapses. Detrimental \\nprocesses, spanning across all disease stages and \\nunderpinning the progressive accumulation of disa-\\nbility, start early and subtly emerge clinically under \\nthe strong influence of age-related biological \\nchanges, which induce immune senescence and \\nexhaustion of compensatory mechanisms.10 The indi-\\nvidual immune system proactivity accounts for the \\nsimultaneous highly variable superimposed relapsing \\nactivity, which overlaps the progressive course and \\nadditionally contributes to the disability accumula-\\ntion. In this wide spectrum of age-related clinical \\nmanifestations, young patients are more likely to \\nexperience relapse onset progressive MS and display \\nan initial floridly inflammatory course, which gradu-\\nally subsides by growing older, while the subclinical \\nneurodegeneration becomes clinically evident. At the \\nopposite extreme lay older patients, who present with \\na PP course and are distinguished by a resistance to \\nthe clinical inflammatory activity, possibly related to \\nundetermined immunological qualitative differences, \\ncompared to SPMS.\\nAlike other neurodegenerative disorders, such as \\nParkinson or Alzheimer diseases, progressive MS is \\npreceded by a prodromal phase of unknown duration \\nbefore meeting its conventional clinical definition. It \\nremains debated whether relapses represent a con-\\ncomitant epiphenomenon to the primary neuroaxonal \\nloss, which potentially promotes the release of highly \\nantigenic myelin fragments, secondarily triggering \\nthe innate and adaptive immune responses. This \\ninside-out model would contrast with the traditional \\noutside-in view of a primary process, starting in the \\nperiphery with a dysregulated immune reaction and \\ncausing an inflammatory response, which eventually \\nlead to the axonal degeneration. The tight intercon-\\nnection between neurodegenerative and inflammatory \\nmechanisms makes the two hypotheses equally likely, \\nleaving the question unresolved. However, evidence \\nof early progressive accumulation of disability inde-\\npendent of relapses discloses a dissociation between \\nthe therapeutic suppression of the inflammatory activ-\\nity and the disease progression. This highlights the \\nneed of shifting our treatments strategies to target \\nmore broadly all pathological mechanisms driving \\nMS, with a specific focus on halting smouldering pro-\\ncesses, which account for the progressive worsening \\nsince the early stage.\\nDeclaration of Conflicting Interests\\nThe author declared the following potential conflicts \\nof interest with respect to the research, authorship, \\nand/or publication of this article: Dr Scalfari received \\nhonoraria for participations to advisory board and \\nconference attendances from Teva, Biogen, Novartis, \\nSanofi-Genzyme, Roche and Celgene.\\nFunding\\nThe author received no financial support for the \\nresearch, authorship, and/or publication of this \\narticle.\\nORCID iD\\nAntonio Scalfari  https://orcid.org/0000-0002-7757 \\n-0293\\nReferences\\n 1. Lassmann H, van Horssen J and Mahad D. \\nProgressive multiple sclerosis: Pathology and \\npathogenesis. Nat Rev Neurol 2012; 8: 647–656.\\n 2. Scalfari A, Lederer C, Daumer M, et al. The \\nrelationship of age with the clinical phenotype in \\nmultiple sclerosis. Mult Scler 2016; 22(13): 1750–\\n1758.\\n 3. Confavreux C and Vukusic S. Natural history of \\nmultiple sclerosis: A unifying concept. Brain 2006; \\n129(Pt 3): 606–616.\\n 4. Kantarci OH, Lebrun C, Siva A, et al. Primary \\nprogressive multiple sclerosis evolving from \\nradiologically isolated syndrome. Ann Neurol 2016; \\n79(2): 288–294.\\n 5. Lorscheider J, Buzzard K, Jokubaitis V, et al. \\nDefining secondary progressive multiple sclerosis. \\nBrain 2016; 139: 2395–2405.\\n 6. Kremenchutzky M, Rice GP, Baskerville J, et al. The \\nnatural history of multiple sclerosis: A geographically '),\n",
       " Document(metadata={'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}, page_content='Multiple Sclerosis Journal 27(7)\\n1004 journals.sagepub.com/home/msj\\nbased study 9: Observations on the progressive phase \\nof the disease. Brain 2006; 129: 584–594.\\n 7. Kappos L, Wolinsky JS, Giovannoni G, et al. \\nContribution of relapse-independent progression vs \\nrelapse-associated worsening to overall confirmed \\ndisability accumulation in typical relapsing multiple \\nsclerosis in a pooled analysis of 2 randomized clinical \\ntrials. JAMA Neurol 2020; 77: 1132–1140.\\n 8. Dal-Bianco A, Grabner G, Kronnerwetter C, et al. \\nLong-term evolution of multiple sclerosis iron rim \\nlesions in 7 T MRI. Brain. Epub ahead of print 23 \\nJanuary 2021. DOI: 10.1093/brain/awaa436.\\n 9. Sucksdorff M, Matilainen M, Tuisku J, et al. Brain \\nTSPO-PET predicts later disease progression \\nindependent of relapses in multiple sclerosis. Brain \\n2020; 143: 3318–3330.\\n 10. Musella A, Gentile A, Rizzo FR, et al. Interplay \\nbetween age and neuroinflammation in multiple \\nsclerosis: Effects on motor and cognitive functions. \\nFront Aging Neurosci 2018; 10: 238.\\nVisit SAGE journals online \\njournals.sagepub.com/\\nhome/msj\\n SAGE journals\\nMS can be considered a primary progressive \\ndisease in all cases, but some patients have \\nsuperimposed relapses – No \\nAnne H Cross  and Robert T Naismith\\nThe “primary progressive MS” nomenclature indi-\\ncates steadily progressive neurodegeneration, perhaps \\npunctuated by periods of quiescence, but with an \\noverall relentless downhill course and without \\nimprovements. It also implies the steady loss of axons \\nwithin the central nervous system (CNS), most fre-\\nquently associated with an impairment in ambulation. \\nThe reasons for the progressive axonal loss are not \\nfully known but likely to be multifactorial.\\nWe contend that not all multiple sclerosis (MS) is pro-\\ngressive from the beginning. Extrapolating this stance, \\nwe argue that not all people with MS have a steady loss \\nof CNS axons beyond what occurs naturally with aging \\nor in association with relapses. The other side of this \\ndebate might argue that progressive MS can be \\nobscured by overlying relapses and by neuroplasticity. \\nWe base our stance that progressive MS is not present \\nfrom MS initiation in all people with MS upon the fol-\\nlowing pillars: (1) clinical cases of bona fide “benign” \\nMS lasting for decades and (2) imaging evidence of \\nnon-progression in some persons with MS.\\nAlthough identifying benign MS before the requisite \\ndecades of follow-up remains controversial, benign MS \\nundoubtedly exists.\\n1 We argue that benign MS would \\nnot exist in a substantial proportion if all people with \\nMS have underlying progressive MS, even accounting \\nfor possible periods of quiescence. The Multiple \\nSclerosis Severity Score was based on the Expanded \\nDisability Status Scale (EDSS) scores of 9892 primarily \\nEuropean MS patients in relation to their disease dura-\\ntions.2 These MS patients were being followed at \\ndedicated MS centers, suggesting that the majority had \\nthe correct diagnosis of MS. The average disease dura-\\ntion of the patients in the study was 11.7 years. The \\nstudy included several hundred people with 15 or more \\nyears duration of MS, 25% of whom had EDSS of 2.5 \\nor less, which is close to a normal neurological exami-\\nnation. Over 200 people were followed more than \\n20 years. Even after 20 years disease duration, 15% had \\nan EDSS of 2.5 or lower. These proportions were simi-\\nlar to those derived in a London Ontario MS cohort,3 \\nsupporting their veracity and the existence of a popula-\\ntion of MS patients with long-standing, minimally \\naltered neurological examinations.\\nIn the United States, the New York State MS \\nConsortium (NYSMSC) reported a retrospective study \\nof over 6000 persons with MS, and observed that \\n19.8% of NYSMSC patients qualified as benign.4 A \\nconservative definition of EDSS ⩽ 2 with ⩾ 10 years \\nduration since symptom onset was adopted and the \\nmean duration since symptom onset was 17 ± 6.7 years. \\nWe argue that it is difficult to reconcile cases of MS \\nthat remain without significant disability accumulation \\nfor 15 or 20 years as having underlying progressive dis-\\nease even after accounting for neuroplasticity.\\nSome may argue that benign MS does not adequately \\ncapture all types of impairment due to its reliance on \\nthe EDSS and ambulation. In particular, the EDSS does \\nnot sufficiently capture cognitive dysfunction. A recent \\nstudy of cognition in benign MS found that after an \\nextensive battery of 16 neuropsychological tests, cog-\\nnitive dysfunction was identified in only 8%.5 This \\nhttps://doi.org/10.1177/13524585211001789\\nhttps://doi.org/10.1177/13524585211001789\\nMultiple Sclerosis Journal\\n2021, Vol. 27(7) 1004 –1005\\nDOI: 10.1177/ \\n13524585211001564\\n© The Author(s), 2021.  \\nArticle reuse guidelines:  \\nsagepub.com/journals-\\npermissions\\nCorrespondence to: \\nAH Cross \\nDepartment of Neurology, \\nWashington University \\nSchool of Medicine, Saint \\nLouis, MI 63110, USA. \\nCrossa@wustl.edu\\nAnne H Cross \\nRobert T Naismith \\nDepartment of Neurology, \\nWashington University \\nSchool of Medicine, Saint \\nLouis, Missouri, USA')]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---AGENT INVOKED---\n",
      "---DECISION: DOCS NOT RELEVANT---\n",
      "---REWRITE INVOKED---\n",
      "---AGENT INVOKED---\n"
     ]
    }
   ],
   "source": [
    "out = graph.invoke(inputs, config=config)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      " \n",
      "\n",
      "Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), which includes the brain, spinal cord, and optic nerves. The symptoms of MS can vary widely from person to person, but common symptoms include:\n",
      "\n",
      "* Vision problems, such as blurred vision, double vision, or loss of vision\n",
      "* Muscle weakness, numbness, or tingling in the arms or legs\n",
      "* Balance and coordination problems\n",
      "* Difficulty with speech, swallowing, or bladder control\n",
      "* Fatigue, depression, or anxiety\n",
      "\n",
      "The exact cause of MS is not known, but it is believed to be an autoimmune disease, where the immune system mistakenly attacks healthy tissue in the CNS. This can lead to damage to the myelin sheath, which surrounds and protects nerve fibers.\n",
      "\n",
      "Diagnosing MS typically involves a combination of physical exams, medical history, laboratory tests, and imaging studies. The following are some common diagnostic tests used to confirm a diagnosis of MS:\n",
      "\n",
      "1. **Magnetic Resonance Imaging (MRI)**: This is the most commonly used test to diagnose MS. MRI can show damage to the myelin sheath in the CNS.\n",
      "2. **Evoked Potentials**: These tests measure the electrical activity of the nervous system and can help detect damage to the nerve fibers.\n",
      "3. **Lumbar Puncture (Spinal Tap)**: This involves inserting a needle into the spinal canal to collect cerebrospinal fluid, which can be tested for signs of inflammation or damage.\n",
      "4. **Blood Tests**: These tests can measure levels of certain proteins in the blood that are associated with MS.\n",
      "5. **Nerve Conduction Studies (NCS)**: These tests measure the electrical activity of the nerves and can help detect damage to the nerve fibers.\n",
      "\n",
      "To confirm a diagnosis of MS, doctors typically look for a combination of these symptoms and test results over time. The disease is usually diagnosed in stages:\n",
      "\n",
      "1. **Relapsing-Remitting MS**: This is the most common type of MS, where symptoms come and go.\n",
      "2. **Secondary Progressive MS**: This type of MS develops after a period of relapsing-remitting MS.\n",
      "3. **Primary Progressive MS**: This type of MS progresses gradually over time, without distinct relapses.\n",
      "\n",
      "Early diagnosis and treatment can help manage the symptoms and slow the progression of the disease.\n"
     ]
    }
   ],
   "source": [
    "out[\"messages\"][-1].pretty_print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "inputs = {\n",
    "    \"messages\": [\n",
    "        (\"user\", \"Which was the first question?\"),\n",
    "    ]\n",
    "}\n",
    "\n",
    "for output in graph.stream(inputs, config=config):\n",
    "    for key, value in output.items():\n",
    "        pprint.pprint(f\"Output from node '{key}':\")\n",
    "        pprint.pprint(\"---\")\n",
    "        pprint.pprint(value, indent=2, width=80, depth=None)\n",
    "    pprint.pprint(\"\\n---\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAj8AAAFNCAIAAABgzJk3AAAAAXNSR0IArs4c6QAAIABJREFUeJzs3XdcU9f7B/ATEkhCwgh7hI0ICgKOKqhFBb8uHIgDJ9aq2LpXSx3VOqiKu9ZRV91W696zLsCFoojK3puwIYOM3x+3v5RaQIiBk5s87z98QUxuPtyM555z7j2HIpPJEAAAAEAqWrgDAAAAAC0G1QsAAAD5QPUCAABAPlC9AAAAkA9ULwAAAOQD1QsAAAD50HAHAAC0FiFfwssT1VZJaqvEYrFMLCLF5TEybR0tXX2arh5V30jbwEQbdx6goihwvRcAaqamsi75ZU3625ryEpG+sbauHlVXj6ZvpF0nlOKO9mkyJKsTymorxbVVEpo2pbJU7ODOcurEMrNh4I4GVAtULwDUh1Qii77MK8kTGlvpOLqzrZ2ZuBN9Ll6+MP1tTXlRnVAg9R1qzDHTwZ0IqAqoXgCoiYQnFffPFPsONfbuw8GdRfnS4qujL/OcPNk+Q4xxZwEqAaoXAOrg/pkihq5WjyEmuIO0rqTYqrgH5WMW2uAOAvCD6gUA6d0+VmjhwPDoaYA7SFsozBKc3ZEzc6OTlhYFdxaAE1QvAMjtwq5cZy+2u69GlC5CnUj6W3jarC3OuIMAnKB6AUBijy4U6xlqe/UxxB2krRXnCO+eKgxZbIs7CMAGrlYGgKwSX1bRtLU0sHQhhEy59K4BRlGXSnAHAdhA9QKArB6cKe7cTxNLF8HZi52VWFuSK8QdBOAB1QsAUoq9U+beU5/OpOIOglPPoSZRl6H5paGgegFAPjKZLCux1jdQzc+P/yRbV119I+28VD7uIAADqF4AkE9afA2d2XYf3vz8/Ly8PFwPb5qRhU7K6+pW2jhQZVC9ACCf9Lc1Du6stnmunJycYcOGvXv3DsvDP8nBnZX+tqaVNg5UGVQvAMinvLjO0aONqpdYLFbsuhriUQo/vJn0jbSNrXRK8uDcDY0DK6QAQDKCGklZkag1ztcQCATr169/+PAhQsjb23vx4sUymWzUqFEIofDwcIRQYGDgqlWrCgsLd+3aFRUVVV1dbWdn99VXXw0cOJDYwpgxY5ycnJycnE6dOiUQCA4dOjRu3LiPHq702FpalIqSOhMrutK3DFQZVC8ASKamUszSb5VP7qFDh65cuTJz5kwTE5MrV64wmUxdXd21a9cuX7585syZXbt2NTIyIppTCQkJo0aNMjQ0vHfv3vLly21sbDp27EhsJCYmRiAQbN26tba21s7O7r8PVzqWPq2mUtwaWwaqDKoXACRTUylh6bfKifJ5eXlMJnPKlCk0Gm3EiBHEja6urgghe3t7Ly8v4hZra+szZ85QKBSE0PDhwwMCAu7fvy+vXjQaLSIigslkNvZwpWMZUGsqJK20caCyYNwLAJKRSWU6rXPC4aBBgwQCwZw5c1JSUpq+Z1JS0sKFCwcOHBgUFCSRSHg8nvy/3N3d5aWrbdB0iEoKNAtULwBIRlefVlFc1xpb9vX13b59O4/HCwkJWbt2rVjccHfc8+fPQ0NDRSLRypUrN27caGBgIJX+s2pzG5cuhFBVqZjB0uirtjUT9BwCQDIsfWpNZWt1lPn6+vbo0ePkyZNbt261tLT8+uuv/3uf/fv3c7ncbdu20Wg0LOXqIzWVEgt7Bt4MoO1B2wsAktHVoxlZaEulyj8NXSQSIYS0tLQmTJhgamr64cMHhBCDwUAIFRcXy+9WXl7u4uJClC6RSFRbW1u/7fWR/z5c6WjaFD0j7dbbPlBN0PYCgHwYutS0+BpnT7ZyN3vq1KkHDx4MHjy4uLi4uLi4Q4cOCCFzc3Nra+tjx44xmcyKioqQkJCuXbtevnz54sWLBgYGx48fr6ysTE1NlclkDY4+/ffhdLoyT23n10gyEmoCxpsrcZuAFKDtBQD52HdkZSQof4IJLpcrEom2bt164cKFkJCQSZMmIYQoFEpERASLxdq0adPly5dLS0u/+eYbHx+fyMjIjRs3du/efcOGDSUlJS9evGhwm/99uHIzZyTU2Hdsowu3gUqB1SkBIB9+tfjWscLhM61xB8Hv4flirgvTsaOSm6FA9UHPIQDkw2TTOOY6rx+Ue/o1vL6XTCbr27dvg//F4XDKysr+e7ufn99PP/2k7KQf27lz559//vnf2/X09Kqqqv57O4PBuHHjRmNbK8kV5qbwvwwyVXZMQALQ9gKAfEQiEVVLe2946rebnBu7T2PTutfV1WlrN3COA5PJ5HA4So3ZgIqKipqaFvR5amlpWVhYNPa/F/fkevfh2LrqKikdIBOoXgCQQG5urq6uLofD2bBhw+XLl0+ePGljYxP3oJxCkXl+2eolRzXlp/PfP63sFwLna2goOGsDAFVUVVX14MGD1NRUhNDSpUu/+eYbortv+PDht2/ftrGxQQh5+RlmJ/E1c30QkUB6aW8elC5NBm0vAFRFRkbGrVu3OnTo0KtXr82bN+fm5s6dO9fe3p7P5zdxRfDh1RmBMyyNLTRrhvXff0ofOYerD5d5aTCoXgDgIRQK6XR6QkLCkSNHvLy8xo0bd/HixYKCgmHDhllaWjZ/OzKp7I/N2V+ONLVywjznRdsQi6THN2SNWWDDZP8zO9T27du9vLz8/PywRgNtCnoOAWgjQqEwMzMTIfTq1augoKA9e/YQN/bv3z8wMJDoFQwLC2tR6UIIUbQoIUtsY67x3j+rbLXsqqIoW7BvefrwmVb1SxdCyNHR8eLFiwih2traAwcOpKWl4csI2gi0vQBoRW/fvs3Pz+/fv39sbOycOXNCQ0PDwsJyc3MlEomtra1ynyv6SknW+1rfoSZqeQ5eebEo+jJPm67Vf0JTY10SiWTv3r0pKSlbtmzJycmJj4/38/PT1VXDHQKgegGgZLdv337+/Pm3335raGgYGhrat2/fKVOm1NbWtsF3aHGuMPpyCUufZuXEdOjI+qiBQlJp8dVFWYLkuBrfocZOnVpwVXJ5efmmTZukUmlERERiYmJtba23t3drJgVtCqoXAJ9FKpVqaWlFRka+f/8+MjLS2Nh4x44d1tbWw4cPJ+axbXs5ybWJL6rSE2pMrOiGZtosfRpLn6arT218Kl0VQqEgIV9SWympqRBLxLK30ZUO7qx23myXznqfs9nU1NSff/65U6dOc+fOfffunZGRUROXkQFSgOoFQMvk5+fT6XQjI6OIiIibN29eu3aNxWKdOnXKzc3N09MTd7p/yc/gl+SIairFNZViLQqltlrJ66rEx8e7uLgod9ZdRJHp6FB19aksA5qhqbZ9B2XOYUhcqf3gwYONGzfOnz+/f//+8fHxHh4eSnwK0GagegHwCTU1Na9fv7aysrK3t1+5cmVsbOy2bducnZ3fvn1rb2/PZmvuDHtDhw7du3evlZUV7iCKqKys1NfX37hx4+nTp+/fv89ms7OyspQ+GAlaD1QvABqQlpYWFRXVs2dPR0fH8PDwmpqaRYsW2dvbV1dXa3K5+kh6ejqXy21w3ilyEYvFNBotNDSUx+OdPHmSyWRqaWlpacEp2SoNqhcAf0tISPjzzz979OgxYMCA/fv3V1dXh4aGtsHUf0B15OfnGxoaIoS+/PLLoKCgpUuXEpfl4c4FGgAHF0BDlZeXI4RevHgxZcqUnTt3IoR4PJ63t3ePHj0QQtOmTZs/fz6UrqatXLmyVRdNbnuWlpZMJpPJZD5//nzIkCFEKzw4OPjs2bO4o4GPQfUCmqK8vDwlJQUhdPfu3T59+hDfR2w2e9GiRbNnzyYOt4cNG2ZgYIA7KWm8fv1aLBbjTtFaiHNw3NzcNm/erKenhxC6c+fOjz/+mJGRgTsaQNBzCNTcmzdvysrK/Pz8Hj16tGrVqunTp4eEhOTn57PZbOL7CIDmq6uru3XrFpvN9vPzO3DggLGxcWBgIK7rIgBUL6BW6urqbt++XVJSMnny5NjY2J07dwYGBgYHBzc90S0ALfX+/fs///xz7NixLi4uFy9e9PX1NTWFRTLbFPQcAtITiUT79u1bvXo1MeoeExNDTBXYpUuXQ4cOBQcHE0sv4o6phmbPnq1m417N5+bmtmLFChcXF2L1tUmTJkkkEpFIVFhYiDuapoC2FyAliUSydu3ajIyMQ4cOlZeXnzp1qnv37jAPUBsj9fVerUEoFAYFBXXo0GHTpk3EWfi4E6kzqF6ABCorKxkMho6Ozrx582JjYx8/fiwWi69du+bt7U2s0wiA6vjw4YOrq2tGRsbPP/88fvx4WLellUD1AioqNTXVyMiIw+HMnTs3Pj7+0qVLenp6L1++dHNzg25AQAqxsbHx8fFTpkxJTEwsKCiAMqZcUL2AqhCLxS9fvrSxsbG0tJw7d25BQcGWLVu4XG5ubq61tTXudKABwcHBO3fubOmCZBqIx+OtW7fOwsLiu+++4/F4xsbGuBOpA6heAKeqqqqYmBhHR0dnZ+eFCxfy+fwVK1ZYWVkJBAIGg4E7HfgEGPdqEZFIpKOjc/HixVOnTq1Zs8bZ2Rl3InKD6gXaWnl5+d27dy0sLHr27Llly5bi4uLZs2dD64qMioqKjIyM4NyElkpKSuLz+Z6enocPH/b09PTy8sKdiJSgeoG2wOPxrl27RqfTx4wZc+XKlTdv3oSEhDg6OuLOBQBOsbGxu3btWr16NRy9KQCqF2gtJSUl586d09fXDwkJuXv3bnx8/ODBg4nrY4B6gJ5DpSBWHevWrdvs2bNDQ0NxxyENaPIDZaqpqTly5IhEIpk9e3ZycrJMJvP19UUI+fv7+/v7404HgCoilph5+vTpjRs3iAaZlpYWXLz4SdD2Ap9LKpXu27cvISFhx44dmZmZt2/f9vf3d3BwwJ0LAFIqLCxctmxZSEhIQEAA7iwqDaoXUIREIjl27FhiYmJERIRAIDhy5EiPHj06deqEOxcAaqKsrIzD4Xz33Xd9+vQZPHgw7jiqCOY5BC1w9+7dpUuXIoT4fH5FRQUxhSCDwZgxYwaULg00bdo0mNavlRBryy1YsCAmJqa6urqmpgZ3IpUD1Qt8QnJy8tatW6OjoxFC7969I4av2Gz23Llzu3TpgjsdwKmwsFAikeBOoc4sLS3XrFnDYrGEQmFwcPCHDx9wJ1Ih0HMIGsDn8+/evduuXbv27dvv2rVLX18/KCiIxWLhzgVUS2VlJZvN1tKCg+C2kJGR8fTp07Fjx2ZlZdna2uKOgx9UL/CP4uLinJwcb2/viIgIoVA4d+5cmNIGAFWzZ8+erKysdevWUSgU3FlwguoFUHV1NZvNTk5OnjNnzvfff9+3b1/ciQA5wPVeuNy8ebNHjx4UCkVfXx93Fmygya/RqqqqZs2atW7dOoSQlZXVjRs3oHQBoPoGDBhgYGAgk8mCg4MLCgpwx8ED2l6aKCcn58SJE1OmTEEIpaWl9ejRA3ciAIAiMjIyoqKiJkyYgDsIBtD20iw8Hg8htGXLFjs7OzMzMzMzMyhdAJCXvb09UbqWLFlSUVGBO06bguqlKXg8XmhoaHZ2NlG9xo4dizsRIL3JkydrbLeVqpk3b97GjRtxp2hTUL3UX3l5OUIoOzt7yZIlsBYDUCIDAwO43ktFcLlcYgD7zp07uLO0Eaheau7x48fff/89QsjLy8vd3R13HKBWVqxYYW5ujjsF+Bcmk/njjz/iTtEWYI55NZeenr53717cKYB6MjMzwx0BfKxnz564I7QRaHuprTdv3qSlpU2aNAl3EKC2xowZA+NeKqhnz56VlZWnTp3CHaR1QfVST1FRUbdv34bFi0Gr4vP5UqkUdwrQAH19/d69e8+cORN3kFYE13upp5cvX7Zv3x5mJgStSiKRUKlU3CmAhoLqBQAAaispKSk+Pp5YzEjNQM+hGqqsrNSQk44AXsHBwfn5+bhTgKa4uLhUVVUdPHgQdxDlg3MO1ZBQKHz58iXuFED9iUQi6LxRfcSccOoH2l5qSE9Pb/78+bhTAPV36NAhuN6LLA4fPow7gpJB9VJDDAYjICAAdwqg/kxMTOCsDbKwsLBYunQp7hTKBNVLDVVVVe3cuRN3CqD+wsLCioqKcKcAzTJgwICwsLDKykrcQZQGqpca4vP5V69exZ0CqL+8vDyxWIw7BWguW1tbHR0d3CmUBs6YVx+hoaGlpaXEz3w+X1dXVyaTSSSSa9eu4Y4G1FNlZSWbzdbSgoNg0tiwYYODg8OYMWNwB1ECeNupj9GjR/N4vPz8/Pz8/PLy8ry8vPz8fAqFgjsXUFv6+vpQushl7ty5L168wJ1COeCdpz4CAwOdnJzq3yKTybp06YIvEVBzISEhMM8huTCZTLVZBgyql1qZMGFC/dmhLCwsJk6ciDURUGc1NTUwzyHpVFRUnD9/HncKJYDqpVYGDhxoY2Mj/7Vr164uLi5YEwF1durUKQsLC9wpQMsYGBhcvXr11atXuIN8Lqhe6mbSpElE88vMzGzChAm44wB1xmKxYNyLjFasWKEGi2LDO0/dDBgwwM7OTiaTQcMLtLavvvqqsLAQdwrQYnZ2dl27dsWd4nPBPIeti18t4eUJRaI2vSxheP8ZqPbiIL8paW9r2vJ5mSwtEyu6Nh0OiTRFSUmJGhzCa6bdu3f37dvX1dUVdxDFwfVerUXIl9w5WZSfyrdxZQlrNWJkWyKWFmYKnL3YAeNh7juNkJmZaW1tTaPBQTD5nDhxIj8/f9GiRbiDKA6qV6vgV0vO7cz1GWpqymXiztLWkl9VZr2vGj7TCi41A0BlCYXCzMxMUg8uQCdPqzixIav/JCsNLF0IoXbe+o6e+lcPwGVA6g/GvciLTqeTunRB9WoVcffLOvgYMtma253i0FGPpk3JTqrFHQS0Lhj3IrV169aR+rx5qF7KV5ApZBlobukiaDOovDwR7hSgdcH1XqTG4XBIvYytpn/JtgaxSKpnpD4TOSuGY06vrYTqpebqT+wCSGfq1Kl8Ph93CsVB20v5+NVSmUTTz4WR1Mnq6jR9J6i9ESNG5Ofn404BFMRgMDgcDu4UioPqBQBQkEQigZOWyUssFg8ZMgR3CsVBzyEAQEGXL1/GHQEojkajicXikpISExMT3FkUAdULAKAgiURCpVJxpwCKO336NHkHL6HnEACgoBEjRuTl5eFOARRnYGBA3qlSoHoBABREpVJhRhVS27x58/Xr13GnUBBZqy4AALsLFy7gjgA+C41GKy4uxp1CQVC9AABAQ4WFheGOoDjoOQQAKGjo0KEw7kVqDAaDwWDgTqEgqF4AAKChbt68uXHjRtwpFAQ9hwAABV24cAHOmCe78vJy3BEUBNULAKAgKF1k5+/v7+fnhzuFgqDnkHwkEkl8fFzT9xGLxRMnB+3es62tQgFNNGbMmIICWMiNxGg0Gox7gbYTuXnNlm0RTd+HQqHo6emT930JSIHP50ulUtwpgOKePn0aHh6OO4WCoOdQ5chksqavABUJhZ98OJVK3f3r4VZIB8A/jh49qqenhzsFUJxMJquqqsKdQkFQvfCrqCgfMTJgZti85JTEqKj77dq57ti2HyF08dKfp88cKykpsrCw8u83cOyYSXQ6ff3GVX/dv40Q6uvfFSF04vglSwurr74e42DvZG/vdO78KaFQsHPHoWkzxiGEJk6Y+vXUbxFCAoFg/4Ff7967IRIJbbh2Y8ZM6tf3f+8/JHw7K3TRwmWBQ4KIJL8f/u3EyUNn/rhuYGD4Ku7Fvv07U1OTOBwjb69u076eZWxMyqk8QesxNDTEHQF8lq5du7q7u+NOoSCoXqri2LEDw4eP3rxpDzES/vvh3878eWxkUIidnWN2dsYfp4/k5GYtDV89cfzU4qLC/PzcH8JXI4SMjf6uKM+fxwiEgoi1W2v5tdbWNmtWb/pp9d8dAlKpdNnyBQUFeRPGf2VoaBQX92LN2qUCAX/woOHtnNvfun1VXr1u37nm5xdgYGAY+/JZ+A9z+wcMDhoxtqqy4uy5kwsXz9y394SOjqavugnqmzZt2rp168zNzXEHAQqi0WhsNht3CgVB9VIVHTp4TPt6FvFzSUnx8RMHly9b5/elP3GLsbHp1m0/z561mMu1NTAwLC3jeXh41X84lUZbsSyCyWQSv/bq2Ufe/fjw0b038a9OHr9sYmKKEArwH8jn1549d3LwoOFDhgRt276+oCDfwsIyIeFNXl7OD9//hBD6ZWfk0MCRc+d8R2yha9ceoV+NSkp67+7u2Ya7BKi6wsJCiUSCOwVQ3KtXr06cOBEZGYk7iCKgeqmKzp2/kP8cG/tULBavi1i+LmI5cQuxBmBJcZG+nn6DD3dzc5eXro88efJYLBaPnzhMfotEImGx2Agh/34D9+zddufu9YkTpt66fdXR0dnd3bOgID8zMz03N/vK1fP1t1NeXqakvxWoiZ07d5qZmeFOARQnlUrpdDruFAqC6qUqGIx/ag+vtAQhFLFum5npv/pkrKy4jT2cyWi4dCGEysp4xsYmWzbtqX8jlUZDCLHZ7H59B9y5e33smEl/3b9NDJKVlfEQQqGTZ3zZu1/9h5iZWSj6xwH1ZGdnhzsC+CydOnVq164d7hQKguqlivT+v4Fla2vf4B1atBy7np5+eXmZubllgwdZQ4YEXbt+8eix/WJxXYD/IIQQm62HEBIKBY09OwCEefPmLV++3NTUFHcQoCBtbW1tbW3cKRQE13upIm/vbhQK5fyFP+S38Pl8+c8MBrO0lNf862w6d/5CIpFcuvxng1vr4Obu7ORy7PjBAP9BxCqrXK6tubnF9RuX5HcTi8V1dXXK+MuAWklLS4M3BqnFxcUtXboUdwoFQfVSRVxrm5FBIdHRD5cuX3Dt+sWjxw5MnDwiKfkD8b+enTpXVVVu2Rpx8+aV6OiHn9xa/4DBrq4d9+zdvmNn5I2bl3f+uvmrr0cLBAL5HYYMCZLJZEOHBhO/UiiUWd8u4vFKZs2ZcuHimXPnTs2aPeXipTOt9ucCstq6dSs0vEhNJBKVlZF1PBt6DlXUrG8XmpmZnz//x/PnMcbGJr179TU1+Xt4vH//wYlJ727dvhrz5NHAAUN9fb9selPa2tqRG37dt/+Xe/duXrlyjsu1HTZ0VP3lwAP8Bz16dK+dc3v5Lb179f153bZDv+/5dddmFovdycO7U6fOrfa3ArJydnbGHQF8Fi8vr59//hl3CgVRWjSCAprjzNacLv1NTG00epamD88qaitFfsFwYK7OFi9eHB4ebmICl7EDDKDnEACgoMTERJFIhDsFUNzr16+XL1+OO4WCoHoBABS0adMmaHiRmlAo5PF4uFMoCMa9AAAKat++fTPuBVSXp6fn2rVrcadQELS9AAAKWrhwYUlJCe4UQHF0Ot3Y2Bh3CgVB9QIAKCg5ORnGvUgNrvcCAGiiHTt2wPVepAbXewEANJGDgwPuCOCzeHt7u7q64k6hIGh7AQAUtHjxYhj3IjVtbW19/YaXrVB9UL0AAAqC673I7s2bNytXrsSdQkFQvUAbEYlEcJyuZtasWUPeM9YAQkggEBQVFeFOoSCYKUr5YKYoYqao17HvKrSji4uLeTxeTU2NRCIRi8VisVgoFN64cQN3QAAAqq2tLS0t5XIbXThQlcFZG6C1pKenXX9+XEtLi1iQjEKhED/ExsbijgaUY9WqVXPmzIHmF3np6urq6uriTqEg6DkErcXfP8DW1pb4mShdCCGimAH1EBsbKxQKcacAiktISFi/fj3uFAqCrxLlMzTVkSFN74/VolL0DLR3795tbW1d/3Y6nR4XF4cvF1Cmn376ycjICHcKoLiamprMzEzcKRREXbVqFe4M6iYnpbZOKDPlavS417uYMktHhr2Lsbu7e0xMTE1NDdFtuHz58iNHjhw9elQsFjs6Ouro6OBOChRnaWlZf6E4QDocDqdbt24kPWke2l7KZ+emW16k6acR11aJbVyYCCEPD48lS5aYmZkhhPT09IYOHXrgwIHIyMji4uJBgwZt3rz56dOnuMMCBa1YsYK8M5QDYtyLpKdsQPVqFfZuLCZL6/lNzT07/O6JPI9eBrp6fx+V9+3bd+rUqQYGBvfv3yducXBwmDdv3sOHD7t06XL48OHAwMDjx4+XlpZiTQ1aLC4uDsa9SI3U13vBGfOtoqKiIuGRuKpMYm7PNLWmU2kacZQgqJWU5ArePy3vNdzEoSOr+Q/Mz8+/cePGiRMnPDw8Ro4c2atXr9aMCZQmJSXFzs5OW1sbdxCgoGfPnh06dGj37t24gygCqpeS1dTUrFq1atKkSZ06dUp/W538qlrAl5bmt2lHokwmE4lEdDq9LZ8UIaTH0TYy1/bsY2hkruBo1oMHD86dO4cQcnV1DQoKsrCwUHZGAMA/RCJRbW2toaEh7iCKgOqlZOfOnTM0NOzXrx/GDEVFRaGhodevX8eY4XOUlJRcuHDh/Pnz9vb2Y8aM8fPzw50INGzFihXz58+H670AFhrRo9UGrl69OnnyZITQyJEj8ZYuhJC+vv6iRYvwZvgcJiYm06ZNu3r16qRJk168eNGnT5/t27dnZWXhzgU+BuNeZAfXe2k04lyDxMTEgwcP4s7yNwaDERAQgDuFEvTo0WPRokWXL1/mcDjz5s378ccfr127hjsU+Ed4eDhc70VqpL7eC3oOFScWi8PDw8eNG9elSxfcWf6loqLi9OnT06dPxx1EyeLi4s6ePXvnzp0RI0aMGDGiffv2uBMBQG6VlZV5eXkkXeILqpeCKisrCwsL8/LyVHBUpqSkZMKECTdv3sQdpFWIRKILFy5cuHCBy+V27949KCgIZp/CZcuWLVOnTiXpmD8gO/jYt9izZ898fHy0tLTatWungqULIWRoaPjLL7/gTtFadHR0xowZc+LEia+//joxMbF79+6rV6+Oj4/HnUsT/fXXX7W1tbhTAMV9+PBh+/btuFMoCKpXCxDLU2VnZz948IDNZuOO0ygajebi4oI7Ratr37790qVLnz9/7unpuXnz5nHjxp06dUogEODOpUG+++47DoeDOwVQXGUqujD4AAAgAElEQVRl5YcPH3CnUBD0HDaLRCJZsWLFgAEDVLOx9RGhUBgZGbl8+XLcQdpUamrquXPnLly40Ldv3+DgYG9vb9yJAFB11dXVxcXFDg4OuIMoAqrXp4lEosTExLy8vAEDBuDO0ixisbhnz54aO3/g9evXb926lZGRMXLkyKCgIFVuJZPd0qVLFy5caGJigjsI0ETQc9iUpKSkYcOGyWQyDw8PspQuoudw+/btGntcMmjQoK1bt27fvp3H4w0ZMiQ8PPzFixe4Q6mn+Ph4kUjTJ6Qmtbi4uKVLl+JOoSBoezVMKBTS6fQDBw4MHDjwoxWqALncvn37/v37CQkJo0ePDg4OZjA0euUa5YqLi3Nzc2v7OcmAssA8h+rm+PHjJSUl8+bNwx1EcVu2bBk7dizUXbns7OwzZ86cPXs2ICAgJCTEzc0NdyIA8Kuuri4oKHB2dsYdRBHQc/gvYrE4Ozu7sLCQ1KULIZSVlZWWloY7hQqxsbFZuHBhVFRUt27djh8/PmXKlNu3b+MORXo7d+4sLy/HnQIojs1mk7R0QdvrXzZv3vzVV1+x2Ww1WPD3w4cPbDabvOvOtbb4+Pjjx4/HxcVNmDBh0qRJuOOQ1dChQ/fu3WtlZYU7CFBQSkrKX3/9RdJ5eaDt9bdt27ZZWloaGRmpQekiVhiB0tUEDw+P9evXHz16lMfjjR8//rfffsOdiJSmT59O0kXlAaG0tPTly5e4UygI2l7o+PHjEyZM4PP5TCYTdxalSUxMfPDgwYwZM3AHIYe9e/fu27dvxowZsMeARikrK8vIyCDpxZGa3vYKCgoiun3VqXQhhMzNzf/44w/cKUgjLCzsxYsXMplsxowZZ8+exR2HNLZs2QLjXqTG4XBIWro0unq9efOGaHh1794ddxblMzQ0XL9+Pay91CJhYWG//fZbYmJiSEjI69evccchAZjnkOxgfS+SqampGT58ODEFg66uLu44raVbt25wIY4Cli5dumbNmu3bt5N39tI2s2PHDlNTU9wpgOL4fH5VVRXuFArSuHEvsVj89OlTOzs7tT+p4dWrV0+fPp05cybuIGR18eLFY8eO7du3D1YAAeqqpqampKTEzs4OdxBFaFb1Wr16dXh4uHqcVdgc3bt3j4qKotFouIOQVVpa2vTp08+ePQsFrEG7du0aP3487ByAhQb1HF67ds3T01NzShfxJ8M0dJ/D0dHx7t27YWFh7969w51FFV2/fh3GvUgtNTX1wIEDuFMoSCOqV3V1tUgk8vX1HT58OO4sbcrIyEhbWxt3CtL7448/vv/++7y8PNxBVE5YWJiBgQHuFEBxPB6PvHNYq3/PYU1NzeDBgx88eIA7CB5LliwZNGhQv379cAchN7FYPHPmzL1791KpVNxZAFCaioqK3NzcDh064A6iCPVve509e1ZjSxdCKDw8/K+//sKdgvRoNJqnp+fRo0dxB1EtK1as4PF4uFMAxRkYGJC0dKl59ZJKpSkpKZMnT8YdBCdjY+M1a9bgTqEOwsLCrl27JhaLcQdRIXFxcXBNIam9fv2avIuwq3P1CgkJoVAouFOohAMHDuTk5OBOQW46OjoUCiUjIwN3EBUSHh5uZGSEOwVQnFAoJG/rWW3HvRISEgwMDNT+oq7m8/f3v337tpaWOh+vtLawsLAZM2Z06dIFdxAAlAPGvVRRx44doXTVd/fuXShdn8nFxQVOEK8vMjKyrKwMdwqgOBj3UjkLFy6Mi4vDnUIVrVy5EncEErtw4QI0vOp7+PAhn8/HnQIo7u3bt2vXrsWdQkFqWL0yMzNpNJqXlxfuIKroq6++gun7FPPmzRtnZ2c1nhhTARs2bDAxMcGdAiiutrY2NzcXdwoFqe24F2hMYWGhubl5dXU1MU8xaKZff/3VwsIiODgYdxAAlIbU8xyqYdsrNTUVejOaYG5ujhCaN29eUlIS7iykUVhYePXqVShdH1mzZk1paSnuFEBxLBaLpKVLPavX3LlzKyoqcKdQdQcOHLh27RruFKRx4MCBefPm4U6hcp49eyYQCHCnAIqD671Ui52dHfTFN8f8+fMRQr///jvuIKru4cOHxcXFAwYMwB1E5cC4F9nB9V6AxN6+fbt69erTp0/jDqKiBAKBv79/VFQU7iAAKJ9AIKiqqiLpEqPq1vaSyWRv377FnYJM3N3dDx48iBCCRUAatGHDhr179+JOoaIWLFhQUlKCOwVQHIPBIGnpUsPqVVdXN336dNwpSIY4+VAgEMydOxd3FtXy3Xff9erVy93dHXcQFZWSkgILyJHa27dvIyIicKdQkLqtukuhUCwtLXGnIKXOnTvz+fyXL1+6u7tr1BqejVmyZMkXX3zh7++PO4jqgnkOya62tjY7Oxt3CgXBuBf4F5lMxuPxLly4MG3aNNxZcIqMjBw0aBC0uoB6q66uLigocHZ2xh1EEerWcyiTyci7VKgqoFAoJiYmdXV1d+/exZ0Fm/Xr11tbW0Pp+iRY34vs2Gw2SUuX+rS95s+fX1hYSKPRiNnl27dvT6PRZDLZsWPHcEcjq6KiIj09vTdv3nTv3h13ljb1/fffd+/efeTIkbiDqK7Ro0fr6OhQqdTk5GRra2s6nU6lUul0+r59+3BHA80ydepUYqW6ysrKiooKGxsboh127tw53NFaQE3GvQICAiIiIogBZC0treTkZISQRCLBnYvEzMzMEEKHDx9OT08PCQkhbhwyZAiNRtu1a5e1tTXugK1i6tSp48ePDwgIwB1EpQkEgvT0dOJn+YJn33zzDdZQoAXs7OwuXbokX/6QON+YdJNuqEnPYWBgIHH4ICeVSrt164YvkZrYtWsXg8FACBFHaoWFhXl5eUeOHMGdS/kEAsHs2bPnzZsHpeuTOnbsKJVK699iY2Mzfvx4fIlAy0yePJk4PJWjUCh+fn74EilCTaoXQmjixIl0Ol3+K4fDGTduHNZEamLEiBEIoR07dnzxxRfEyOLjx4/Je55Sg5KTk/39/VesWOHp6Yk7CwmMGzfuo8Z3YGAgk8nElwi0jIODg6+vb/1hI1tb21GjRmEN1WLqU72GDh1afzlKR0fHvn37Yk2kVq5cuSI/3C4oKDh8+DDuREpz48aNQ4cORUVFEfMXg0/y9PRs3769/FculwtHiqQTGhoqb35RKJQvv/zSysoKd6iWUZ/qVb/5ZWhoCP0YShQcHFxZWSn/lUKhPHnyRD2aX7t27Xr06BF5L9jEZeLEicbGxgghKpUaGBgIy56Rjq2trbz5xeVyybh+glpVr6FDhzo4OCCE7O3toeGlRBkZGR+dm5qXl7dnzx58iZRj8eLFdDp93bp1uIOQj5eXV8eOHYkRL/lJPYBcJk+eTJwu0KNHj/odV2TRrHMOxXVSfrW0GXfEb2zwlH379o0ZGVpVJsad5dNkMhlLn0alUXAH+YSFCxe+ffs2Nze3pqZGIpZJ67SrqqpexybFv0qxt7fHnU5BM2fODA0N9fHxkb9VZDKZvpE27lwtU1MhlmL6aI4ZGZr8PmfY4NGyOgaWj5tMhvSNSHbWdHW5WHWuUTLSt/bp1u+J5Enw8Ikq9IUpk7ENaRStT38rfuJ6r/fPKt88qigtEDHZVKUGBAghpEVF1eViUy7d80tDl856uON8QkJMRdzD8uqyOqo2kkqlUqmUOB2RjMR1dVpUqpbWv/oeOBY6ucm1Tp7s7gONDE1Vfa6sxxeKE2OrjS3p5cUaOtOgsRU9N7nW2YvtO9RYV0/Vy9iDs8XJL6vM7Bil+Rr6ejUTXZfKyxdynZlefQztO7CauGdT1evZrdKSvDovPyM9sh2QkktVaV3snRJuO4Z3Hw7uLI2KucarKBF79OboG6n61/rnkIhl5cXC+6cLAqdZmljRm/EIDCRi2cnILI/eRpYOTCZb1b+1W1WdSFpWKLx3In/sYhuVbTfXiaQHf8zoPdLM1IbJ0IVmQLNU8kRPrxV36K7n2k2/sfs0Wr2e3iit5Il7BJo1+L9A6R5fKDS30encTxULWNTlEiEfdRugQesQntueMWymFcdMFUv18fVZPQJNzWzgDPV/nNyQNmmZHZOlirXhwIr0ITO4LH0VLa6q7K9T+e28WW5fNFzAGj5ro6xIVJIrhNLVlnqNMM9J5leXq0zv8/8ryRNW8MQaVboQQn3HWT69Xoo7RQNePyx38tKD0vWRviGW0ZdVcaWxZ7dKvfsZQelSTN8Qy/fPqurqGh7abbh6leQKZTJVP5VA/UilqDhXiDvFx0pyhRSkcW8Gjhk9Ja4ad4oG5KXy4avwvwxNddLia3CnaEBOEp/NgddLcXVCKS+34ZHChqtXdYXE1IasA/LkZW7PrOSpXNurplJiytXEN4ODB5uXr3IHEzIZUs3+TLwYulQzG2ZNhcp9fKhUiqGZig6gkoKlk25FScPVq+Eh3zqhtE7QyqHAf4hqpTqqd5Qm4ktV5hTfNlVeJEKq1+gsL6rDdYq8iuPlCeTTzqoOXr4Qwev1GfjVErG44a9FtbpaGQAAgIaA6gUAAIB8oHoBAAAgH6heAAAAyAeqFwAAAPKB6gUAAIB8oHoBAAAgH6heAAAAyAeqFwAAAPKB6gUAAIB8oHoBAAAgH3WuXhKJJD4+DncK0CrS0lKGDe/7OOo+8Wt1dXVS8gfcoUBzweulBj76DLY9da5ekZvXbNkWgTsFaBU0Go3N1qNR/55metqMkOvXL+IOBZoLXi818NFnEEOAVtpuTk4Wl2vbShuXk8lkTcwqLRIqf3mLpp/xI22zE1Rci/ZY8zdoa2t/4vgl+Y0iUcNrKICPyGSyvPxcaytuaz9L0y86vF6k1uBnsO0prXrxeCW/7IyMjX1K09bu0qX7w4d39+4+5uDghBC6eOnP02eOlZQUWVhY+fcbOHbMJDqdnpySOGfu1PURO37b/0tqapK5uWXY9Lk9e/oRW8svyNu1a0vsy6c6OnSXdq5Tp37r2r4DQmj7jg0PHt5dvHD5rj1bc3OzN0XusuHaHTi06+nTqJqaahsbu/HjvgrwH4gQWr9x1V/3byOE+vp3RQidOH7J0sIKIfQq7sW+/TtTU5M4HCNvr27Tvp5lbNzUqsHNf8amd4JG+errMQ72Tvb2TufOnxIKBWf+uMFmsxvc89//MDcnJ+v40QvEA48dP+hg7yR/G4R+NcrNzf2bsPkjRgbMDJuXnJIYFXW/XTvXwYOGb9j4E0IocuOvXbt0DxkfWFZWeuHimQsXz5ibW5w6cYV4eINvPHx7BZt379/+umtzWlqysZGJvYNTSkrikd/P6ejoCASC/Qd+vXvvhkgktOHajRkzqV/f/yGE/jx74t5ft0aPmnDgwK+80pJ27VwXL1xua2tPbK2xT9B/X/RHj+9duHA6LT2FydT9opvP7FmLDQ05CKEGX6/Gwmia7OzMrdt+fv/hrZ6efo/uvebPC5dKpf0H9Jg+bfb4cVOI+/ywbH5FRfmunb8npyTOXzB9xbKIfQd2ZmVlmJtZTJgwtbSUd+nyn9XVVd7e3RYvXE7s86HD+8yZteTuXzdfvXrOZusF+A/q1Mn70O97cnKyHOydFixY2t7FDSFUVFTY4JdbRUV5E59BWxv7seOGfPSHBAQMWvbDGgW+cptPOdVLIpEsXTa/tIw3b154aWnJvv07vb26Et/avx/+7cyfx0YGhdjZOWZnZ/xx+khObtbS8NUIIaFQ+NOa8Dmzl1haWB36fc/aiGWnTlwxMDDk8UrmzJ1qbW0ze9ZiCoVy69bVefOn7dl1lNhgTU31gUO75s8LFwj4nb275RfkffiQMHzYKAN9w4eP762LWG5tbePm2nHi+KnFRYX5+bk/hK9GCBkbmSCEYl8+C/9hbv+AwUEjxlZVVpw9d3Lh4pl7dx9jMJpafbGZz9jETtBAz5/HCISCiLVba/m1bDa7sT3fxy9gY+Tq9PRUYkfduHnZxsaOqF5paSlZWRnfhM0nNnjs2IHhw0dv3rSHSqUaGnBmTJ/z275fiP9atXLjd9/P9vLsMnrUBG2dv1dubOKNp1EKCwsWL/mmXTvXZT+sffos6srV89OnzdbR0ZFKpcuWLygoyJsw/itDQ6O4uBdr1i4VCPiDBw1HCL1///b06aOLFi0Xi8Vbtqz7ecPK3b8e/uQn6KMX/d27eFtb+/79B5eVlZ47f6qmtubnddtQQ69X02E0SuTmNVlZGbO+XVRbW/Mq7oWWlpa0yfXcamtrt+1YP39uuA6dvvPXTRsjV3t4eK1YFlFYVLB5y9pfd28hSghCaPPWdd9+s3BKaNgffxw58+fxe3/dXLRgGYPJ3LZ9/U8/fX/k8DkajSaWiBv8ciO20NhnUE9Pf/68cHmkW7evZmSkTv96dmNvmP2/ndTWVsJKhsqpXu/fv01K/rDyx/V9/AIQQllZGddvXBKJRJWVFcdPHFy+bJ3fl/7EPY2NTbdu+3n2rMXEr3NmLyGOsKZNmx02c+LrNy+/7N3v6LH9HEOjzZG7aTQaQqh/wOCJk0dcuXZ+zqzFRJ/D4oXL3dzciS1YWVr/fvAM0U0xaNDwoOCAqKj7bq4duVxbAwPD0jKeh4eXPOcvOyOHBo6cO+c74teuXXuEfjXq+YuY3r36NvHXNfMZG9sJOjqauBIulUZbsSyCyWQSvza253v27EPbGhEV/cDBwen165e5udn5+bmFhQXm5hYPHt5hs9hdunSvra1BCHXo4DHt61ny7Xt26iz/2bV9BxqNZmxsIn+tS0qKG3zjzZm9RI+t14a7Ab/bd67x+fyVK9YbGRn37On3+s3LJ08fjx835eGje2/iX508ftnExBQhFOA/kM+vPXvupLxgrFu71cjIGCE0cmTIrt1bKyorDPQNmv4EffSiL1ywVN5/SKPRjh0/KBQK6XT6f1+vT4bRHAUFeS7tXAOHBCGExoye2JyHzAyb36NHL+L+Gzb+tGDeDw4OTu7IMzb26dNnUfK7DRo4bPiwUQihsLB5Dx7enTB+qo9Pb4TQhHFf/bxhZV5ejq2tfWNfbsQWGvsMMplMYsvEQefOXzfN+naRmZl5Yx/8jMy0ds7tP39fKad6FRUXIoSs/r8zncu1lUqlfH5tbOxTsVi8LmL5uojlxH/JZDKEUElxEfErk/H3G93c3JL40kEIPX0aVVRcODiwt3z7dXV1xUWFxM8MBkNeSAgpqUm/H96bmPiOaAWWlvIaDFlQkJ+ZmZ6bm33l6vl/hf//LTemmc/Y2E7QzOrl5uYu/xZrYs/r6+l39u4WFXV/4oSp129e8vLsUlrGu37j0pTQGfcf3OnZq4/8GK1z5y+a/+yNvfGKiwo1rXoVFxeyWCyiDlEoFCsrbmFhPkLoyZPHYrF4/MRh8ntKJBIWiy3/lfHvzyavpJhfW9v0J6j+i058bM+dP3X7zrWiogI6nSGVSsvLy8zNLf4b8pNhNEf/gMEnTv6+45eNkyZO43CMmvMQus7f/eHa2joIIXn3g6mpWUVF+T93o//dw6SjrYMQkn8vmZqZE32DxK9NfJ1+8jMokUg2Rv7k6tqRKGaNffCrq6ua83d9knKql7W1DUIoPj7OpZ0r0RQzMTE1MDDklZYghCLWbTMzNa9/fysrbnpGav1btGnaCCGpVIIQKi3j+fj0njFtTv07yN/KTKZu/dtfvnr+ffgcb6+u3y1ZydJl/bhqiVTWcEO7rIyHEAqdPOPL3v3q325k9IlO2GY+Y2M7oemNqyv5cckn97yfX0DkpjVZWRkPHtz5bsnKUl7J6T+P9e7Vt363Yf0v0+Zo4o33eX8W+Vhb29TU1KSlpTg6OtfV1aWkJHp5dSVeFGNjky2b9tS/M5XWwBcC8dmUSCWf/ATVf9FlMtnSZfMTk96FTp7RoUOnR4/unfrjSBOfzWaGUXvTvp7F4RgdO37w+o1LM6bPDRoxRuFNUSgU4qCt+Zr+Ov3kZ/DkqcNp6Sn7fztJtN4ae8MQx0OfTznvj/Yubt269vht347CwvzyirKo6AfLl60j+kOJO8iHfJtDT0+/oqK8mQ85enS/lRU3Yt02opuR+e/9W//FY7P1EEJCoaBFYZr/jI3tBND0nu/Zs8+WrRE/b1jJZOr27tWXL+DvO7Bzy7YIotuw+c9S/7VW7I2nlgb8L/DMn8eXLp//v/5D4l7HisXiKZNnELuovLzM3Nyy+WeytOgT9Pr1y9iXz5YtXUsM++fmZH10h49er5aGUVcUCmVU8PhBA4dv3Rax45eNzk4uHTp4tNmzN/112rSMjLQjR/dNnPC1/O2hrK/cxijteq85s5dwubbZOZmGBpydvxwixn68vbtRKJTzF/6Q343P539yU507f/H27evEpPfNeVRFZbmzkwuxr0UiUS2/Vj7IyWAwS0t58l+5XFtzc4vrNy7JtyYWi+vq6lr6lzbxjA3uBND0njfQN+js3e3Dh4TBg4bTaDQ9tl7fPv979y6+frfhJzEZTB6vRP6rYm88tWRgYDh71mI6nZGentq1S499e08QV3F07vyFRCK5dPlP+T0/uYta9AmqqCxHCBH9EPJf5Z+Uj14vBcKoK6FQiBBisVhTpsxECCUlf6BSqXp6+iW8YuIOMpmsqKiglZ69iS+3pkkkkg2RP9nY2MlPjFTiV25jlNP2EovF384OHT1qorW1DYVCqaqqrK6uZrPZXGubkUEhZ8+dXLp8Qa+efXi8kgsXT/8csV3+nm5Q6OQZT548XvLdrDGjJ3I4Rs+eRUukkrWrNzd4Zy+vrjdvXr52/aK+nsGZs8erqioz0lOJyxE8O3W+fuPSlq0RHu5eenr6vr5fzvp20Y8rl8yaM2XY0FFSieTmrSv9+w8eFTy+RX9sY88okUga3Akt3JdqiEKhNL3n/fwCXsQ+DRwykvh12LBRN25e7vNlC2q/h4f33Xs3Tpz8XU9Pv2OHTo6Ozgq88dTS+w8JGyN/mjv7O5q2tpaWVn5+rpGRMZVK7R8w+PKVc3v2bs8vyHNp55qSkvQ46q/fD/7ZxPm3n3wd6+vg5qGjo7Nv/84hQ4LS0pJPnDyEEEpPSyEuNfvo9VIgjLpatfp7NovdtUuPJ08fEz06CKEvuvncvnW1s3c3I47x6TPHsrIy2rXOO7mxL7dPPvCP00c/fEgYMnjE1Wt/X/1iZGTcu1dfpXzlNkY51YtGo3Xt0uPosf1isZi4RY+tt2P7AXt7x1nfLjQzMz9//o/nz2OMjU169+pramLW9Nasrbg7dxzcvXfb8RMHKRRKu3auQSPGNnbnqVO+KeWV/LIzUk9PP3DIyDGjJm7ZFvEq7kVn7279+w9OTHp36/bVmCePBg4Y6uv7Ze9efX9et+3Q73t+3bWZxWJ38vDuVO/UtWZq4hkb2wktfQr10/Se79Wzz5Mnjy0s/u4Nd3Pt2Nm7W4u6DcNmzC0tLTl6bL+hAefbbxc6Ojor8MZTSxbmlpaW1hsif5J/B7Vzbr9j+wEGgxG54dd9+3+5d+/mlSvnuFzbYUNH0T411NT8T5CpqdnyZet+3bV51U/fdezQacvmvYd+33Pu/Klevfo0+HopEEYtubm637x15eGjeyYmZosWLnN390QIzfp2kVAoXL9hJYvFHjZ0lEAoqKysaI1nb+zLzcmxXROPKikpPnzkN4SQvHQRp/D07tVXKV+5jWl4WO/ZzVKRAHn2adYZLwSJREKlUuUX80+bHjJm9MSvpsxUVlBS+Myd8PIOj22g1SWA08oxWybmCk+GtDx6q1aqNnBpd9bAUAtjS9U6ZfTE+qxeIy045i1IJX9bSiSSR4//+ml1+OZNuzt7d2vNmBic2ZwesthWV5+KO8i/HPwxPXCGLVNPtVKRSPTlIq4zo2MP/f/+l3KOboRC4bezQ83MLDw7ddbW1omPfyUQCJycXJSy8dZWXV09bkJgg/8VNmMeceFFc5B6JwB1lZWVMW/BdJ8evZ2dXIQi4cOHdxkMBtda0ycwA2pAOdWLQqH8r/+Qe/duHvp9j46OjoOD88of1390lqTK0tXV/W3viQb/S1/PoPnbIfVOAOqKxWL79xv45Mmj23eusdl6Hu5e8+f/QFxJCgCpKad66ejojB0zaeyYSUrZWhvT0tIipkD8TKTeCUBdGRubzJ61aPasRbiDAKBk6rxCCgAAAHUF1QsAAAD5QPUCAABAPlC9AAAAkA9ULwAAAOQD1QsAAAD5QPUCAABAPlC9AAAAkA9ULwAAAOQD1QsAAAD5NDxTlA6DIkWUNg+j6ehMqg5D5Xa7jq6WTKqJRzkccx2VezEQ4lhoUzTx1fg0E2sGonx6Jao2ZmLNoFBVLhWJMNlUGq3hD2LDnwM9jnZxpoaubYpRfnqtvrHKrWmkZ0ArytK4N4NUKkuPrzZSseVREEIULUppgRB3CpXDrxYX5wh09VTu4yOVSEvzRbhTkFhuci3HrOE11huuXmY2dIoKHnaqOy0qMrOl407xMVMbenMWV1UzpQXCdp1VcV1srjOztkJpa6urjbJCkZOnKr5etq66VaXweilOh0Exs214ie1G217WzoyHZwtaORj4x1+n8p06sZgslTt45JjpmNvSoy4W4g7Spu4ez+s51AR3iga4+xrkJNVmvKvGHUS13Dme13uEKr5enftx3j8pL8rWuN4Lpbh1OMfLz7Cx/214bWVCQkxFcly1p58xx1yHSoO+9lYhrpOWFQpf3St199Vv30UPd5xGvXlUnvG+1r2XkZEFnUpV24Z5bZW4vFj04HRByHc2+pyG+yuwk0llZ3/Jte/INrfXNTRVub7NtlRTUVdeLLp7PH/qGnsVPPIjSCWyI+syvfoamVgzDIw1+vVqJpFQWlEsena92DfQyNaV1djdmqpeCKH0hJq4B+UF6QJqI+NmqkaGkFQqoWqRYx1uKo1SJ5RaOzO9+hjauOjijvMJqW+qXz8sL84RqWuvsok1vbxI5OjB6jHEmKGr6m+h57dKk2Kr6LrU0gJswyoSqcD5EQMAABT3SURBVFRLSwvX28HMll5WWOfYidV7hAm+FM315Bov+VU125BWnKNCw5YyJJNKZVQtFWqcMNnU2iqxratu574cc7uG+wwJn6heckK+VHnxWpFIJAoMDLx16xbuIM0kozNV/Vvyv8jyZmgxGaLrqtDHuDnEIplEgm1UMiQkZNu2bRYWFlieXSaTqf5BxkfqhFKpKn16YmNjT5w4sXnzZtxB/tH8l7W5bW06kxyfagpVSySuIUtakoLdqzpoOhQavotbxFK+Nh3eDy2gTVetfUXTkUlkApK+gqQMDQAAQMOpYfVq37497ggAaAR7e3sNvJpCnVCpVHNzc9wpFKRu1YtKpTIYTQ30AQCUJSMjg6Ku5/BoBrFYXFRUhDuFgtSweiGEJBIJ7iAAqD/o5yA7CoVia2uLO4WC1K16IYRYLFZJSQnuFACov8TERNwRwGcpLy+vqKjAnUJBali9TE1NMzMzcacAQP1B24vsxGKxvb097hQKUsPq5eLiEh8fjzsFAOoP2l5kl5iYyGI1OpmFilPD6tWvX79r167hTgGA+jMxUcWpBUHzlZWV2dnZ4U6hIDWsXoaGhp6enhcvXsQdBAA1BwPMZBcdHe3u7o47hYLUsHohhBYtWnTkyBHcKQAAQHWlpKQYGxtzOBzcQRSkntWLxWLNnDlz586duIMAoM4cHR1xRwCKe/369YABA3CnUJx6Vi+EUP/+/S0tLTds2IA7CABqKy0tDXcEoLjDhw9D9VJRwcHBlpaWZ8+exR0EAPVkYGCAOwJQUExMjK2trbW1Ne4gilPn6oUQmjx5cnV19apVq3AHAUANkfdCV7Bnz56ZM2fiTvFZ1Lx6IYRCQ0O7dOmyYMGCjIwM3FkAAAC/S5cuOTo6kvdsQ4KKrqWtXEOHDnVzc1u0aNHIkSMnTJiAOw4AaqJ9+/YwSy8ZXbhwYc+ePbhTfC71b3sRnJ2dz549K5VKAwICHjx4gDsOAOogMTERVkghndDQ0IULF+ro6OAO8rk0pXoRJk2adObMmWfPnoWEhPz111+44wAAQJv64YcfxowZQ/Y+Q4JG9BzWx+FwlixZkpycvHfv3jt37nTt2jUoKAh3KABIicFgQM8hifzwww+jRo3q0qUL7iDKoVltL7l27dpt2rTp66+/TkhI8PHxOXToUHp6Ou5QAJCMQCCAnkOy+Pbbb7t27ao2pUtzqxfB0dFx+fLlDx48YLPZS5YsmTx58unTp6urq3HnAoAcYIUUUsjIyJg6dWpoaGhwcDDuLMpEgUMnuYSEhCtXrhCNsH79+vXr1w+m0AagCUOHDt27d6+VlRXuIKBRu3btunv37o4dO0h9YXKDNG7cqwkdO3bs2LEjQuj58+f37t2bMGGCj4+PlZWVr6+vegxyAgA0R0JCQnh4+IgRI9R1viFoezXl3bt3jx49io6Ozs7O9vX17dWrl5eXl4WFBe5cAKgEaHuppg8fPuzevdvAwGDmzJlq/OpA9WqWioqK6OjouLi4x48f02i0bt26devWrXPnzqamprijAYBNWFjYqlWrLC0tcQcBf0tJSdm9e3dBQcE333zTq1cv3HFaF1SvFsvJyXn+/Pnz58+zs7MrKio8PT29vLy8vLycnJxwRwOgTUHbS3U8efLk5s2b7969++abb/r06YM7TluA6vVZcnNzX79+HRcXFxcXZ25uLpPJOnbs6OHh0bFjR/Ku+QZAM0H1wk4sFp85c+aPP/6wtrYeP358z549cSdqO1C9lKaysjIhISEhISE+Pj4hIUFXV7dPnz4mJiZubm6urq56enq4AwKgZFC9MIqLi4uOjj58+PDo0aPHjh1rY2ODO1Fbg3MOlUZfX9/Hx8fHx4f4NTc3Nzk5+fXr1wcOHPjw4YOBgYGrq2u3bt2sra1dXFyMjY1x5wXgc8H1Xm0vLy/vypUrV69eNTExCQ4Ofvr0Ke5E2EDbq43k5OR8+PAhLy/v2bNnSUlJFArFxcXFxcXFzc3NycnJwcEBd0AAWgzaXm2mvLz83r17165dKywsDAwMHDJkCJfLxR0KM6heeJSUlCQlJSUlJWVmZsbHx2dnZzs7Ozs5Obm4uDg7O7dr1w4aZ0D1QfVqbTwe7+7du3fu3ElNTf3f//73v//9z9vbG3coVQE9h3iYmJiYmJj4+voSv4rF4pSUlNTU1KSkpJiYGBqNFh8f7+jo6FSPoaEh7tQA/IuLiwvuCOopOzs7Jibm5s2b2dnZ/v7+YWFh6jQ/obJA20tFVVRUpKWlpaampqampqWlpaSkeHh48Pl8e3t7R0dHBwcHBwcHuNoM4AVtL+WKi4t7+PDhw4cPxWJx//79e/bs6eXlhTuU6oK2l4oyMDDw9vau30tQVlaWlpaWnp6elpZ2//799PR0Pp/fu3dvbW1t+/9nZ2eHNTUAoGVqa2ujoqISExPPnTvn4ODw5ZdfRkZGwkB4c0D1Ig0Oh9OlS5f6HQjV1dWZmZmpqakZGRkXL17MyMjIysqyt7d3cnLicrnyeqavr481OFBb0HOosJSUlMePHz9+/DgxMbFnz57+/v7nz583MDDAnYtMoOdQrchksoyMjIyMjMzMTPkPVCrVzs7Ozs6uY8eOJiYmdnZ2tra2WloavTgOUAroOWwRPp8fExMTHR395MkTFovVq1evXr16wVkYCoO2l1qhUCjEkFj9G8vKyjIzMzMzM8vKyqKiojIzM7OysqysrIgyZm9vb2NjY2trC7PVgZbicDhw+PtJ79+/j46Ojo6OTkxM9PHx8fX1nTFjhpmZGe5cpAfVS/1xOBwOh/PR8G9OTg5RxlJTU+/du5eVlVVcXGxra2tjYyOvatbW1vAZA00oKyujUCi4U6ii0tLSmJiYmJiYqqoqHo/n6+s7Z84cOAVDuaB6aSgul8vlcuvPiiYWi7OysrKzszMzM4n5rmJiYiorK23/n52dHVHb4Nx9ABr04sULomOwuLjYx8enZ8+evr6+MJrVSmDcCzRFIBBk/b/MzMzs7Gw6nf7u3TuilSYvbFwuF0qaBho9evSOHTs0vM85JyeHGM169+6dvb29r69vjx49YA6tNgDVC7RYdXU10UqTF7acnBwKhWJtbS0vacQPMDexWurSpYtMJtPS0pJKpcS/FApl9OjR4eHhuKO1EYlE8vz584cPH8bExEilUmI0y9fXl0aD3qy2A9ULKEdVVRXROCPqGfFD+/btRSIRUclsbGyIH9hsNu6w4LNMnz795cuX9Ue8uFzunj171H7Z8ZSUlCdPnkRHR7948SI4ONje3t7Hx8fW1hZ3Lg0F1Qu0ovLycnkly87OJn7Q1tb28fGhUCjEQBpR2FgsFu6woLkePHiwevXqiooK+S1TpkyZPXs21lCtpaamJiYmJikp6fLly/r6+j169PD19e3evTvuXACqF2hzZWVlubm5xEn88sLGYDBcXFxMTU3rdzwyGAzcYUHDwsLCYmNjiZ/t7e23b99ubW2NO5QyEWctxcTEpKam+vj49OvXz9vbG07BVSnQSwvaGnEGv7u7e/0beTye/CR+YnLSrKwsPT09W1tbLy8vFoslL2k6Ojr4soO/jRs3LiUlhWh++fn5qUfpKi4uJs6/KC8vFwgEPj4+CxYs6NSpE+5coGHQ9gKqq7i4OCsrq6ioKDk5Wd4DaWRkZGNj4+HhYWBgIB9Lg9Hytjdz5swXL17Y2dn98ssvpJ5u49mzZ/Hx8bdu3aqoqCDOv/Dx8YHRWdUH1QuQTEFBQXZ2dmFhYXJysnwszdTU1MbGxsnJydLSksvlEg01KGmt6v79+ytXrgwODp47dy7uLC2Wk5MTFRUVHR0dExPTpUsXomPQ2dkZdy7QAlC9gDrIz8/Pzs7Oy8tLS0vLyckhGmrEKJqTk5OFhYW841EzJ3jM+lCb8YFfnCPkV4lFAqlIKFXKZsV1YiqNqpTpNgyM6XVCCZNNNbaic53oDu4sbXrLXqns7OyZM2devXq10bRiMVGuoqOj27dvTyyw5+PjQ6VSPz8/aHtQvYDays/Pz8rKysvLS09Pl3c8WllZ2djYdOrUSV9fX37GI+6kraW8WPTiTkXiiwq2MVPfnEXTptLoVJoOVYumciVcJkVioVgskkjEkqqi2sriWisnXW8/fTu3Zp2MGhcXt3LlypycHPm5JHLEiq/EaJaVlRXRN8jlclvn7wBtB6oX0Cw5OTn1Ox6JS62JzkY3NzcjIyOinpH92622Wnz/T15eKt/M2YhtoqulRb7ZCKvLBKUZ5Tp0mV+QiaVjU2ef3r9/f8uWLXl5ecSq5Tdu3KisrIyJiYmKiiotLeXxeETF6tq1axvGB60OqhcAiChjhYWFKSkpRCstLy/P1ta2e/fuNBpN3utIlimR3r+oeXm3XNeYxbEm/VwnNaX8spxKa2dGn5FGDfZQnjlz5uDBg8XFxfJbOnbsmJWVRUwz6OPjY2Rk1KaJQVuB6gVAA6RSaVZWVkFBQWpqqrzXsbi4uF+/fkKhUF7PbGxsVG2CiWe3yj68qLH1JkehbaailFIGXTJsxse7+sCBAydOnKh/3bRMJjt8+PBH12MAtQTVC4DmEovF8ovS5NdZi8Xi+ufu29vbW1lZ4SppCU+r4h5VW3dUw4tqedmVLGbdwEn//Gk///zz9evXq6urPzoTx8rK6tKlSzgygjYF1QuAz1JX93/t3W9MG+cdB/DnOBv8D4wN5n9NCAQoSRuttCUhTbQoaaJCELRsEco2VWlKG6XppiVNp0wV0jptmlRtqtbsVar+z4t2q9R02roQkTZqs42uTQNhTexQxZgkxmAb+3w+4/vj2wtHHgUnbSUf9tnfzwvLusOPf7zAX36+555HWLwOliRJo6OjgUAg0Zm1trYmZvPb7fby8nJFKxn/JPTfT7nqO3MwuhLmrzGFBbHuff//z2BoaMjpdLIsy3EcwzCyLMuybLFYRkZGMloprASkF0D68TyfiLTZ2VmHw5EINrvdznFcIsmampoqKyvtdrvFYvmWY/b393Mc19PTc+DAgeVnPa7oqTfnVt2bC2te3MbsZKC+me7Y+bVLWaFQyOVyORyOiYmJqakpj8czPDycuRphhSC9AFZIJBJJtmgsy46NjbndbkEQkpfQko8pN0vr7u72er1arXbt2rVHjx5tbGxMnpJl+Y3fuOvW19DZNxU+7a5fnNmxp8xWhzUw8x3SCyCTWJZNXkJLPkqStHhPmcTz3t5elmUTm0s1NDTs3r17YGAgMch/TgeuXpYqmvJicl3Yx/Ehpv9gjneZ8I2QXgBZJxwOL76WlnjOMMzinzEajR0dHUeOHLHZbMd+PrluR0Pm6l1p7i8823aX1TbpM10IZBLSC0Ad2tvbl6zJJMtybW3t84dfd14UKxqzsfE68eehazcu/+Jn76R32PAcR/GRXY9n170KsMKwjCmAOsiynEivxLQ6q9Xa2dnZ1dV14W8RY0WK62Q5rNhmmBj2ZroKyDCkF4A6UBRltVqtVuvWrVs3b97c1tZGCOEX4iOeqxWtefcdmrlKf3Ui0rAOW3LnL6QXgDrs379/48aNS1aRuDbJ2eqV2okqMH/j/Q9edH71qVZTVFvT8tD2/XfUthFCXj1xxFZeT9Oa0c/eEyXhzuZNj/Q8q9fdLOPCxdPDH748H/RU2lbLcnoWs1/OaDV63QtIr3yW+/NrAXLD4ODg8gWQIiFJFBR5O4bxHTs+yHFMb9eh7p0HJUn408tPerxfJc6ePXciMH/jsR//vq/r0PjEyMhHryaOnx879dY7z5WYyvq6Dres2XBj5ooixRFCayj/jDK/OagEei8AFYsERVqryPZUp8++YjJan9x7jKY1hJD29Q/97sX+0c9O9nUfIoTYyux7fvAriqLsdWvHv/zQMfnvXeRpQYid/PsfVtd/b/DRlxKbZvn80woFmKZIw86ISowMaoH0AlAxQZC1eq0SI192/jMY8v7y199PHpEkIcjcnCuh1eqSEyCtpdUu9zgh5OrUWIQLbu4cSO73WFCg1MaP2iJaU4ivjvIa0gtAxSiKCDFFWpAw629reaB7x1OLD+qKUlxjo2ltPC4RQuZDM4kwU6KeJUQhHotIK/BGkLWQXgAqZjJrJBevxMgGfUmEC1XYVn2HYowWQgjLBZWoZwkxJhpKlGrsQBXQegOomNFMx0VFWpA1q+9zucemr19KHonx0du/pKZqDUUVnB/7hxL1LCHERFMp0iuvofcCUDFbXVE05Fdi5Ae3Pn7Jee746z/dsmlPsdF6+cq/4nFp749euM1LLKVV99/TM/r5SVGMtazZyIR9l5znik1lSpTHR/jqu/LuLjdYDOkFoGKltkKNllpgeZ2pML0jl5fVHRw8/tdTfzxz9jVCUXXVrZs2/PAbX9XXfVijKfxi/JRjcrTBvr6mqjnMKhKu4VmuYZ2y+6VBlsM6hwDq9vF7Pq+HKl+VR4tFcaFY0O3f8+wdmS4EMgm9F4C6tXUUT70xR8gt0yvEzL3w0sDy47IsEyJTVIqL37t2Pr3h3r50VXjJce7EX4ZSniq31vkC15Yf73rwQOf9/bcakJ2L3P1AcbrKA5VC7wWgeh+8NrMg6Sw1qT/QJUkKMSnWtI3H47IsJ+/NWsygN+t0aVuEiecX2EjgFicpQlJ8BOn1Jcmlp5aOFhWnL3j2Pf8dJkNCTkJ6AageFxbf+u108xZ7pgtZCdcnZu/bZmq+B71XvsOMeQDVMxRr2reX+l3zmS5Ecaw/arZSiC5AegHkiPZtFr1ODHrCmS5EQcKC6HXM7dqHTSmBIL0AckfX3ipKjOZqgEli3POl9yfP1We6EMgWSC+A3NH7RDUfYgPToUwXkmZccMH5sXvgmbrCInxkwU2YtQGQa868PTcfIOZqs6YoF9ZSCrhDfDgy8Azu7oKvQXoB5CDH5+Gz7/rMlUZbo6WAVmu/EphmZq4E2rdbOnZaM10LZB2kF0DOOn8m6DjPCjwxlhmKKwyFOkV2AksvSZDCvijr44QF3t5s2PJwmRbfFkIqSC+AHDft5K5ciPg9gtfFFeppnVFDFVCZLmqpIr2W8Uf5qGSt1pnMdEu7cVWbEbkFt4H0AsgXsixzjBRhRCGWdX/1BVrKaKINJbRGi8SCbwXpBQAA6oN/cwAAQH2QXgAAoD5ILwAAUB+kFwAAqA/SCwAA1AfpBQAA6vM/yjbvR17XJ94AAAAASUVORK5CYII=",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "try:\n",
    "    display(Image(graph.get_graph(xray=True).draw_mermaid_png()))\n",
    "except Exception:\n",
    "    # This requires some extra dependencies and is optional\n",
    "    pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "memory = MemorySaver()\n",
    "\n",
    "state_msg = SystemMessage(\"You are a chatbot which can retrieve information from documents based on a query.\\n\"\n",
    "                          \"You should always think about what to do. Do not use any tool if you think it is not necessary.\\n\")\n",
    "\n",
    "model = ChatOllama(model=\"llama3.2:latest\")\n",
    "\n",
    "agent_executor = create_react_agent(model, [retrieve], checkpointer=memory, state_modifier=state_msg)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "StateSnapshot(values={}, next=(), config={'configurable': {'thread_id': 'def234'}}, metadata=None, created_at=None, parent_config=None, tasks=())"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "config = {\"configurable\": {\"thread_id\": \"def234\"}}\n",
    "agent_executor.get_state(config=config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(Image(agent_executor.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "What's your name?\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Tool Calls:\n",
      "  retrieve (15c82e66-a4a7-4758-83fa-a316814f1070)\n",
      " Call ID: 15c82e66-a4a7-4758-83fa-a316814f1070\n",
      "  Args:\n",
      "    query: What is the chatbot's name?\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: retrieve\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 1}\n",
      "Content: comitant epiphenomenon to the primary neuroaxonal \n",
      "loss, which potentially promotes the release of highly \n",
      "antigenic myelin fragments, secondarily triggering \n",
      "the innate and adaptive immune responses. This \n",
      "inside-out model would contrast with the traditional \n",
      "outside-in view of a primary process, starting in the \n",
      "periphery with a dysregulated immune reaction and \n",
      "causing an inflammatory response, which eventually \n",
      "lead to the axonal degeneration. The tight intercon-\n",
      "nection between neurodegenerative and inflammatory \n",
      "mechanisms makes the two hypotheses equally likely, \n",
      "leaving the question unresolved. However, evidence \n",
      "of early progressive accumulation of disability inde-\n",
      "pendent of relapses discloses a dissociation between \n",
      "the therapeutic suppression of the inflammatory activ-\n",
      "ity and the disease progression. This highlights the \n",
      "need of shifting our treatments strategies to target \n",
      "more broadly all pathological mechanisms driving\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 0}\n",
      "Content: A Scalfari  \n",
      "Centre of Neuroscience, \n",
      "Department of Medicine, \n",
      "Imperial College London, \n",
      "Charing Cross Hospital, \n",
      "Fulham Palace Road, London \n",
      "W6 8RF, UK. \n",
      "a.scalfari@imperial.ac.uk\n",
      "Antonio Scalfari  \n",
      "Centre of Neuroscience, \n",
      "Department of Medicine, \n",
      "Imperial College London, \n",
      "Charing Cross Hospital, \n",
      "London, UK\n",
      "1001789 MSJ0010.1177/13524585211001789Multiple Sclerosis JournalA Scalfari\n",
      "research-article20212021\n",
      "Controversies in Multiple Sclerosis\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}\n",
      "Content: Multiple Sclerosis Journal 27(7)\n",
      "1004 journals.sagepub.com/home/msj\n",
      "based study 9: Observations on the progressive phase \n",
      "of the disease. Brain 2006; 129: 584–594.\n",
      " 7. Kappos L, Wolinsky JS, Giovannoni G, et al. \n",
      "Contribution of relapse-independent progression vs \n",
      "relapse-associated worsening to overall confirmed \n",
      "disability accumulation in typical relapsing multiple \n",
      "sclerosis in a pooled analysis of 2 randomized clinical \n",
      "trials. JAMA Neurol 2020; 77: 1132–1140.\n",
      " 8. Dal-Bianco A, Grabner G, Kronnerwetter C, et al. \n",
      "Long-term evolution of multiple sclerosis iron rim \n",
      "lesions in 7 T MRI. Brain. Epub ahead of print 23 \n",
      "January 2021. DOI: 10.1093/brain/awaa436.\n",
      " 9. Sucksdorff M, Matilainen M, Tuisku J, et al. Brain \n",
      "TSPO-PET predicts later disease progression \n",
      "independent of relapses in multiple sclerosis. Brain \n",
      "2020; 143: 3318–3330.\n",
      " 10. Musella A, Gentile A, Rizzo FR, et al. Interplay \n",
      "between age and neuroinflammation in multiple \n",
      "sclerosis: Effects on motor and cognitive functions.\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}\n",
      "Content: Washington University \n",
      "School of Medicine, Saint \n",
      "Louis, MI 63110, USA. \n",
      "Crossa@wustl.edu\n",
      "Anne H Cross \n",
      "Robert T Naismith \n",
      "Department of Neurology, \n",
      "Washington University \n",
      "School of Medicine, Saint \n",
      "Louis, Missouri, USA\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 1}\n",
      "Content: tip of the pathological iceberg.\n",
      "These observations challenge the dichotomy between \n",
      "relapsing and progressive disease, supporting a one \n",
      "stage disorder model of MS, where all patients \n",
      "exhibit a progressive course since the disease onset, \n",
      "which can be overlapped by relapses. Detrimental \n",
      "processes, spanning across all disease stages and \n",
      "underpinning the progressive accumulation of disa-\n",
      "bility, start early and subtly emerge clinically under \n",
      "the strong influence of age-related biological \n",
      "changes, which induce immune senescence and \n",
      "exhaustion of compensatory mechanisms.10 The indi-\n",
      "vidual immune system proactivity accounts for the \n",
      "simultaneous highly variable superimposed relapsing \n",
      "activity, which overlaps the progressive course and \n",
      "additionally contributes to the disability accumula-\n",
      "tion. In this wide spectrum of age-related clinical \n",
      "manifestations, young patients are more likely to \n",
      "experience relapse onset progressive MS and display\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}\n",
      "Content: The reasons for the progressive axonal loss are not \n",
      "fully known but likely to be multifactorial.\n",
      "We contend that not all multiple sclerosis (MS) is pro-\n",
      "gressive from the beginning. Extrapolating this stance, \n",
      "we argue that not all people with MS have a steady loss \n",
      "of CNS axons beyond what occurs naturally with aging \n",
      "or in association with relapses. The other side of this \n",
      "debate might argue that progressive MS can be \n",
      "obscured by overlying relapses and by neuroplasticity. \n",
      "We base our stance that progressive MS is not present \n",
      "from MS initiation in all people with MS upon the fol-\n",
      "lowing pillars: (1) clinical cases of bona fide “benign” \n",
      "MS lasting for decades and (2) imaging evidence of \n",
      "non-progression in some persons with MS.\n",
      "Although identifying benign MS before the requisite \n",
      "decades of follow-up remains controversial, benign MS \n",
      "undoubtedly exists.\n",
      "1 We argue that benign MS would \n",
      "not exist in a substantial proportion if all people with\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "My name is not explicitly mentioned in the document you provided. However, I can tell you that my creator is Antonio Scalfari, and I am a chatbot that can retrieve information from documents based on a query.\n",
      "\n",
      "As for my actual name, I don't have one. I am an AI designed to assist users with their queries, and I don't have a personal identity or a specific name assigned to me.\n"
     ]
    }
   ],
   "source": [
    "config = {\"configurable\": {\"thread_id\": \"def234\"}}\n",
    "\n",
    "input_message = (\n",
    "    \"What's your name?\"\n",
    ")\n",
    "\n",
    "for event in agent_executor.stream(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": input_message}]},\n",
    "    stream_mode=\"values\",\n",
    "    config=config,\n",
    "):\n",
    "    event[\"messages\"][-1].pretty_print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Why some scientists do believe that there is no such thing as relapsing-remitting MS? \n",
      "Once you answered, would you show me the parts of the document that support your answer?\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Tool Calls:\n",
      "  retrieve (dbc240a3-95c1-40db-84e5-5f282d3d4120)\n",
      " Call ID: dbc240a3-95c1-40db-84e5-5f282d3d4120\n",
      "  Args:\n",
      "    query: Why some scientists do believe that there is no such thing as relapsing-remitting MS?\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: retrieve\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}\n",
      "Content: The reasons for the progressive axonal loss are not \n",
      "fully known but likely to be multifactorial.\n",
      "We contend that not all multiple sclerosis (MS) is pro-\n",
      "gressive from the beginning. Extrapolating this stance, \n",
      "we argue that not all people with MS have a steady loss \n",
      "of CNS axons beyond what occurs naturally with aging \n",
      "or in association with relapses. The other side of this \n",
      "debate might argue that progressive MS can be \n",
      "obscured by overlying relapses and by neuroplasticity. \n",
      "We base our stance that progressive MS is not present \n",
      "from MS initiation in all people with MS upon the fol-\n",
      "lowing pillars: (1) clinical cases of bona fide “benign” \n",
      "MS lasting for decades and (2) imaging evidence of \n",
      "non-progression in some persons with MS.\n",
      "Although identifying benign MS before the requisite \n",
      "decades of follow-up remains controversial, benign MS \n",
      "undoubtedly exists.\n",
      "1 We argue that benign MS would \n",
      "not exist in a substantial proportion if all people with\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 2}\n",
      "Content: decades of follow-up remains controversial, benign MS \n",
      "undoubtedly exists.\n",
      "1 We argue that benign MS would \n",
      "not exist in a substantial proportion if all people with \n",
      "MS have underlying progressive MS, even accounting \n",
      "for possible periods of quiescence. The Multiple \n",
      "Sclerosis Severity Score was based on the Expanded \n",
      "Disability Status Scale (EDSS) scores of 9892 primarily \n",
      "European MS patients in relation to their disease dura-\n",
      "tions.2 These MS patients were being followed at \n",
      "dedicated MS centers, suggesting that the majority had \n",
      "the correct diagnosis of MS. The average disease dura-\n",
      "tion of the patients in the study was 11.7 years. The \n",
      "study included several hundred people with 15 or more \n",
      "years duration of MS, 25% of whom had EDSS of 2.5 \n",
      "or less, which is close to a normal neurological exami-\n",
      "nation. Over 200 people were followed more than \n",
      "20 years. Even after 20 years disease duration, 15% had \n",
      "an EDSS of 2.5 or lower. These proportions were simi-\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 0}\n",
      "Content: of the disease, among patients with no permanent \n",
      "motor impairment, especially when relapses with \n",
      "poor recovery, which can potentially cloud the pro-\n",
      "gressive accumulation of disability, are uncommon. \n",
      "This was highlighted by George Ebers’ group by \n",
      "addressing the clinical course of single attack pro-\n",
      "gressive MS, which is a rare phenotype distinguished \n",
      "by a single demyelinating  episode at onset, followed \n",
      "some years later by the progressive phase. Because \n",
      "of the lack of ongoing relapses, in this subgroup, the \n",
      "progression mostly presented clinically with exer-\n",
      "cise-induced ambulation worsening and could be \n",
      "pinpointed after 8 mean years from onset, at an aver-\n",
      "age EDSS of 2, therefore much earlier than in classic \n",
      "SPMS cases.6\n",
      "In line with these early intuitive observations, recent \n",
      "data indicate that a continuous progression independ-\n",
      "ent of relapsing activity (PIRA) is commonly observed \n",
      "during the RR phase. The pooled analysis of the two\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 1}\n",
      "Content: tip of the pathological iceberg.\n",
      "These observations challenge the dichotomy between \n",
      "relapsing and progressive disease, supporting a one \n",
      "stage disorder model of MS, where all patients \n",
      "exhibit a progressive course since the disease onset, \n",
      "which can be overlapped by relapses. Detrimental \n",
      "processes, spanning across all disease stages and \n",
      "underpinning the progressive accumulation of disa-\n",
      "bility, start early and subtly emerge clinically under \n",
      "the strong influence of age-related biological \n",
      "changes, which induce immune senescence and \n",
      "exhaustion of compensatory mechanisms.10 The indi-\n",
      "vidual immune system proactivity accounts for the \n",
      "simultaneous highly variable superimposed relapsing \n",
      "activity, which overlaps the progressive course and \n",
      "additionally contributes to the disability accumula-\n",
      "tion. In this wide spectrum of age-related clinical \n",
      "manifestations, young patients are more likely to \n",
      "experience relapse onset progressive MS and display\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 0}\n",
      "Content: tinct. There are no surrogate markers or universally \n",
      "accepted definition for the continuous unremitting \n",
      "disability accumulation and defining the clinical phe-\n",
      "notypes of MS can be challenging even for experi-\n",
      "enced clinicians.\n",
      "The current phenotypical distinction of relapsing \n",
      "remitting (RR), secondary progressive (SP) and pri-\n",
      "mary progressive (PP) MS provides a standardized \n",
      "terminology, which enhances homogeneity in clini-\n",
      "cal trials. However, despite the variable patterns of \n",
      "evolution, there are no biological reasons for discern-\n",
      "ing different phenotypes. Pathological mechanisms \n",
      "underlying acute attacks and progression are known \n",
      "to be tightly intermingled and to occur concomitantly \n",
      "since the early phase of the disease, irrespective of \n",
      "clinical symptoms. The same wide spectrum of cen-\n",
      "tral nervous system tissue alterations is seen across \n",
      "all stages, with only quantitative, rather than qualita-\n",
      "tive differences.1 Both PP and SP MS share similar\n",
      "\n",
      "Source: {'source': 'C:/Users/Carlini/Desktop/Gianluca/scalfari-2021-ms-can-be-considered-a-primary-progressive-disease-in-all-cases-but-some-patients-have-superimposed.pdf', 'page': 1}\n",
      "Content: tion. In this wide spectrum of age-related clinical \n",
      "manifestations, young patients are more likely to \n",
      "experience relapse onset progressive MS and display \n",
      "an initial floridly inflammatory course, which gradu-\n",
      "ally subsides by growing older, while the subclinical \n",
      "neurodegeneration becomes clinically evident. At the \n",
      "opposite extreme lay older patients, who present with \n",
      "a PP course and are distinguished by a resistance to \n",
      "the clinical inflammatory activity, possibly related to \n",
      "undetermined immunological qualitative differences, \n",
      "compared to SPMS.\n",
      "Alike other neurodegenerative disorders, such as \n",
      "Parkinson or Alzheimer diseases, progressive MS is \n",
      "preceded by a prodromal phase of unknown duration \n",
      "before meeting its conventional clinical definition. It \n",
      "remains debated whether relapses represent a con-\n",
      "comitant epiphenomenon to the primary neuroaxonal \n",
      "loss, which potentially promotes the release of highly \n",
      "antigenic myelin fragments, secondarily triggering\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Some scientists believe that there is no such thing as relapsing-remitting MS because they argue that not all people with multiple sclerosis (MS) have a steady loss of CNS axons from the beginning. They propose that \"benign\" MS cases exist, where patients experience long-term, but relatively mild symptoms without significant progression.\n",
      "\n",
      "The 2021 study by Gianluca Scalfari and colleagues suggests that a continuous progression independent of relapsing activity (PIRA) is commonly observed during the relapsing-remitting phase (RRMS). This challenges the traditional dichotomy between relapsing and progressive disease, supporting a one-stage disorder model where all patients exhibit a progressive course since disease onset.\n",
      "\n",
      "The study also highlights that young patients are more likely to experience relapse-onset progressive MS, displaying an initial inflammatory course that gradually subsides with age. In contrast, older patients present with a primary progressive (PP) course and show resistance to clinical inflammatory activity, possibly due to immunological qualitative differences.\n",
      "\n",
      "These findings imply that the traditional classification of MS into RRMS, SPMS, and PPMS may be too simplistic and that all patients with MS may share similar pathological mechanisms. The study's authors propose a more nuanced understanding of MS, recognizing that progression is a continuous process from disease onset, rather than a dichotomous event between relapsing and progressive phases.\n",
      "\n",
      "Overall, the study suggests that the concept of relapsing-remitting MS may be an oversimplification, and that a more comprehensive understanding of the disease's progression is necessary.\n"
     ]
    }
   ],
   "source": [
    "# config = {\"configurable\": {\"thread_id\": \"def234\"}}\n",
    "\n",
    "input_message = (\n",
    "    \"Why some scientists do believe that there is no such thing as relapsing-remitting MS? \\n\"\n",
    "    \"Once you answered, would you show me the parts of the document that support your answer?\"\n",
    ")\n",
    "\n",
    "for event in agent_executor.stream(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": input_message}]},\n",
    "    stream_mode=\"values\",\n",
    "    config=config,\n",
    "):\n",
    "    event[\"messages\"][-1].pretty_print()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "llama",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
